<div id="page0" style="width:595.3pt;height:793.7pt">
<p style="top:28.7pt;left:500.9pt;line-height:13.9pt"><span style="font-family:AdvPA18C,serif;font-size:13.9pt">Review</span></p>
<p style="top:69.8pt;left:35.9pt;line-height:23.9pt"><span style="font-family:AdvPA189,serif;font-size:23.9pt">Efficacy of Vitamin C Supplementation on</span></p>
<p style="top:95.7pt;left:35.9pt;line-height:23.9pt"><span style="font-family:AdvPA189,serif;font-size:23.9pt">Collagen Synthesis and Oxidative Stress</span></p>
<p style="top:121.6pt;left:35.9pt;line-height:23.9pt"><span style="font-family:AdvPA189,serif;font-size:23.9pt">After Musculoskeletal Injuries</span></p>
<p style="top:166.3pt;left:35.9pt;line-height:17.9pt"><span style="font-family:AdvPA189,serif;font-size:17.9pt">A Systematic Review</span></p>
<p style="top:202.9pt;left:35.9pt;line-height:12.0pt"><span style="font-family:AdvPA183,serif;font-size:12.0pt">Nicholas N. DePhillipo,*</span><sup><span style="font-family:AdvPA183,serif;font-size:8.5pt">&#x2020;</span></sup><sup><span style="font-family:AdvPA183,serif;font-size:12.0pt"> </span></sup><span style="font-family:AdvPA183,serif;font-size:12.0pt">MS, ATC, CSCS, Zachary S. Aman,</span><sup><span style="font-family:AdvPA183,serif;font-size:8.5pt">&#x2020;</span></sup><sup><span style="font-family:AdvPA183,serif;font-size:12.0pt"> </span></sup><span style="font-family:AdvPA183,serif;font-size:12.0pt">BA, Mitchell I. Kennedy,</span><sup><span style="font-family:AdvPA183,serif;font-size:8.5pt">&#x2020;</span></sup><sup><span style="font-family:AdvPA183,serif;font-size:12.0pt"> </span></sup><span style="font-family:AdvPA183,serif;font-size:12.0pt">BS,</span></p>
<p style="top:216.9pt;left:35.9pt;line-height:12.0pt"><span style="font-family:AdvPA183,serif;font-size:12.0pt">J.P. Begley,* MD, Gilbert Moatshe,</span><sup><span style="font-family:AdvPA183,serif;font-size:8.5pt">&#x2020;&#x2021;&#xa7;</span></sup><sup><span style="font-family:AdvPA183,serif;font-size:12.0pt"> </span></sup><span style="font-family:AdvPA183,serif;font-size:12.0pt">MD, PhD, and Robert F. LaPrade,*</span><sup><span style="font-family:AdvPA183,serif;font-size:8.5pt">&#x2020;</span></sup><sup><span style="font-family:AdvP4C4E74,serif;font-size:8.5pt">k</span></sup><sup><span style="font-family:AdvPA183,serif;font-size:12.0pt"> </span></sup><span style="font-family:AdvPA183,serif;font-size:12.0pt">MD, PhD</span></p>
<p style="top:234.8pt;left:35.9pt;line-height:12.0pt"><span style="font-family:AdvPA186,serif;font-size:12.0pt">Investigation performed at the Steadman Philippon Research Institute, Vail, Colorado, USA</span></p>
<p style="top:263.3pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPA189,serif;font-size:9.0pt">Background:</span><span style="font-family:AdvPA183,serif;font-size:9.0pt"> Recent investigations on the biochemical pathways after a musculoskeletal injury have suggested that vitamin C</span></p>
<p style="top:274.3pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPA183,serif;font-size:9.0pt">(ascorbic acid) may be a viable supplement to enhance collagen synthesis and soft tissue healing.</span></p>
<p style="top:288.2pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPA189,serif;font-size:9.0pt">Purpose:</span><span style="font-family:AdvPA183,serif;font-size:9.0pt"> To (1) summarize vitamin C treatment protocols; (2) report on the efficacy of vitamin C in accelerating healing after bone,</span></p>
<p style="top:299.1pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPA183,serif;font-size:9.0pt">tendon, and ligament injuries in vivo and in vitro; and (3) report on the efficacy of vitamin C as an antioxidant protecting against</span></p>
<p style="top:310.1pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPA183,serif;font-size:9.0pt">fibrosis and promoting collagen synthesis.</span></p>
<p style="top:324.1pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPA189,serif;font-size:9.0pt">Study Design:</span><span style="font-family:AdvPA183,serif;font-size:9.0pt"> Systematic review; Level of evidence, 2.</span></p>
<p style="top:338.0pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPA189,serif;font-size:9.0pt">Methods:</span><span style="font-family:AdvPA183,serif;font-size:9.0pt"> A systematic review was performed, with the inclusion criteria of animal and human studies on vitamin C supple-</span></p>
<p style="top:349.0pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPA183,serif;font-size:9.0pt">mentation after a musculoskeletal injury specific to collagen cross-linking, collagen synthesis, and biologic healing of the bone,</span></p>
<p style="top:359.9pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPA183,serif;font-size:9.0pt">ligament, and tendon.</span></p>
<p style="top:373.9pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPA189,serif;font-size:9.0pt">Results:</span><span style="font-family:AdvPA183,serif;font-size:9.0pt"> The initial search yielded 286 articles. After applying the inclusion and exclusion criteria, 10 articles were included in the</span></p>
<p style="top:384.9pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPA183,serif;font-size:9.0pt">final analysis. Of the preclinical studies evaluating fracture healing, 2 studies reported significantly accelerated bone healing in the</span></p>
<p style="top:395.8pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPA183,serif;font-size:9.0pt">vitamin C supplementation group compared with control groups. The 2 preclinical studies evaluating tendon healing reported</span></p>
<p style="top:406.7pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPA183,serif;font-size:9.0pt">significant increases in type I collagen fibers and scar tissue formation with vitamin C compared with control groups. The 1</span></p>
<p style="top:417.7pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPA183,serif;font-size:9.0pt">preclinical study after anterior cruciate ligament (ACL) reconstruction reported significant short-term (1-6 weeks) improvements in</span></p>
<p style="top:428.7pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPA183,serif;font-size:9.0pt">ACL graft incorporation in the vitamin C group compared with control groups; however, there was no long-term (42 weeks) dif-</span></p>
<p style="top:439.6pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPA183,serif;font-size:9.0pt">ference. Of the clinical studies evaluating fracture healing, 1 study reported no significant differences in the rate of fracture healing</span></p>
<p style="top:450.6pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPA183,serif;font-size:9.0pt">at 50 days or functional outcomes at 1 year. Vitamin C supplementation was shown to decrease oxidative stress parameters by</span></p>
<p style="top:461.6pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPA183,serif;font-size:9.0pt">neutralizing reactive oxygen species through redox modulation in animal models. No animal or human studies reported any</span></p>
<p style="top:472.5pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPA183,serif;font-size:9.0pt">adverse effects of vitamin C supplementation.</span></p>
<p style="top:486.4pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPA189,serif;font-size:9.0pt">Conclusion:</span><span style="font-family:AdvPA183,serif;font-size:9.0pt"> Preclinical studies demonstrated that vitamin C has the potential to accelerate bone healing after a fracture, increase</span></p>
<p style="top:497.4pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPA183,serif;font-size:9.0pt">type I collagen synthesis, and reduce oxidative stress parameters. No adverse effects were reported with vitamin C supple-</span></p>
<p style="top:508.4pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPA183,serif;font-size:9.0pt">mentation in either animal models or human participants; thus, oral vitamin C appears to be a safe supplement but lacks clinical</span></p>
<p style="top:519.3pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPA183,serif;font-size:9.0pt">evidence compared with controls. Because of the limited number of human studies, further clinical investigations are needed</span></p>
<p style="top:530.3pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPA183,serif;font-size:9.0pt">before the implementation of vitamin C as a postinjury supplement.</span></p>
<p style="top:544.2pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPA189,serif;font-size:9.0pt">Keywords:</span><span style="font-family:AdvPA183,serif;font-size:9.0pt"> ascorbic acid; collagen synthesis; fracture healing; ACL reconstruction; collagen cross-linking; oxidative stress</span></p>
<p style="top:584.6pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">The healing of musculoskeletal tissues, such as bone, ten-</span></p>
<p style="top:595.5pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">dons, and ligaments, is dependent on the capacity of colla-</span></p>
<p style="top:606.5pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">gen synthesis and cross-linking.</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">7,20,34</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">Poorly developed</span></p>
<p style="top:617.5pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">extracellular matrices derived from collagen can lead to</span></p>
<p style="top:628.4pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">inadequate tissue structures and biomechanical strength,</span></p>
<p style="top:584.6pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">which can result in unsatisfactory outcomes and an</span></p>
<p style="top:595.5pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">increased risk for reinjuries. Basic science investigations</span></p>
<p style="top:606.5pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">on the biochemical pathways after a musculoskeletal</span></p>
<p style="top:617.5pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">injury have suggested that vitamin C, also known as</span></p>
<p style="top:628.4pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">ascorbic acid, may enhance collagen synthesis and soft</span></p>
<p style="top:639.4pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">tissue healing.</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">22,24,28,31</span></sup></p>
<p style="top:650.4pt;left:316.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">Vitamin C has an essential role in connective tissue heal-</span></p>
<p style="top:661.3pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">ing, being a cofactor for prolyl hydroxylase and lysyl hydrox-</span></p>
<p style="top:672.3pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">ylase.</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">22,28</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">These enzymes catalyze the hydroxylation of</span></p>
<p style="top:655.5pt;left:35.9pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">The Orthopaedic Journal of Sports Medicine, 6(10), 2325967118804544</span></p>
<p style="top:664.5pt;left:35.9pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">DOI: 10.1177/2325967118804544</span></p>
<p style="top:673.0pt;left:35.9pt;line-height:8.1pt"><span style="font-family:AdvPS697C,serif;font-size:8.1pt">&#xaa;</span><span style="font-family:AdvPA183,serif;font-size:7.5pt"> The Author(s) 2018</span></p>
<p style="top:742.4pt;left:290.1pt;line-height:8.5pt"><span style="font-family:AdvPAEBA,serif;font-size:8.5pt">1</span></p>
<p style="top:694.9pt;left:35.9pt;line-height:6.5pt"><span style="font-family:AdvPAEB8,serif;font-size:6.5pt">This open-access article is published and distributed under the Creative Commons Attribution - NonCommercial - No Derivatives License (http://creativecommons.org/</span></p>
<p style="top:703.3pt;left:35.9pt;line-height:6.5pt"><span style="font-family:AdvPAEB8,serif;font-size:6.5pt">licenses/by-nc-nd/4.0/), which permits the noncommercial use, distribution, and reproduction of the article in any medium, provided the original author and source are</span></p>
<p style="top:711.8pt;left:35.9pt;line-height:6.5pt"><span style="font-family:AdvPAEB8,serif;font-size:6.5pt">credited. You may not alter, transform, or build upon this article without the permission of the Author(s). For article reuse guidelines, please visit SAGE&#x2019;s website at</span></p>
<p style="top:720.3pt;left:35.9pt;line-height:6.5pt"><span style="font-family:AdvPAEB8,serif;font-size:6.5pt">http://www.sagepub.com/journals-permissions.</span></p>
<img style="position:absolute;transform:matrix(.374269,0,-0,.3851852,-38,-6.671956)" src="data:image/png;base64,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">


<p style="top:71.0pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">proline and lysine residues of procollagen, promoting the</span></p>
<p style="top:82.2pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">proper folding of the stable collagen triple-helix conforma-</span></p>
<p style="top:93.5pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">tion.</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">9,22</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">In addition to its role in collagen synthesis, vitamin</span></p>
<p style="top:104.7pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">C acts as a powerful antioxidant by neutralizing deleterious</span></p>
<p style="top:115.9pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">reactive oxygen species (ROS) responsible for cell apoptosis</span></p>
<p style="top:127.1pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">during the inflammatory phase.</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">1,14,16</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">Cell culture studies</span></p>
<p style="top:138.4pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">have also reported that vitamin C can induce tendon-</span></p>
<p style="top:149.6pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">derived stem cell mobilization, osteoblast growth and</span></p>
<p style="top:160.9pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">differentiation, and fibroblast stimulation.</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">8,11,18,21,26</span></sup></p>
<p style="top:172.1pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">Therefore, vitamin C has been increasingly studied for its</span></p>
<p style="top:183.3pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">contributions to the treatment of musculoskeletal injuries</span></p>
<p style="top:194.5pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">in both clinical and in vitro trials.</span></p>
<p style="top:205.5pt;left:45.8pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">Although laboratory studies have reported that vitamin</span></p>
<p style="top:216.7pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">C is essential for the formation of collagen fibers and cell</span></p>
<p style="top:227.9pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">differentiation, there is controversy surrounding the effi-</span></p>
<p style="top:239.2pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">cacy of vitamin C as a supplement for clinical treatment.</span></p>
<p style="top:250.4pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">Therefore, the purposes of this systematic review were to</span></p>
<p style="top:261.6pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">(1) summarize vitamin C treatment protocols; (2) report on</span></p>
<p style="top:272.8pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">the efficacy of vitamin C in accelerating healing after bone,</span></p>
<p style="top:284.1pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">tendon, and ligament injuries in vivo and in vitro; and (3)</span></p>
<p style="top:295.3pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">report on the efficacy of vitamin C as an antioxidant pro-</span></p>
<p style="top:306.5pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">tecting against fibrosis and promoting collagen synthesis.</span></p>
<p style="top:317.7pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">It was hypothesized that vitamin C supplementation would</span></p>
<p style="top:329.0pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">result in reduced oxidative stress and accelerated tissue</span></p>
<p style="top:340.2pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">healing when compared with control groups.</span></p>
<p style="top:374.3pt;left:35.9pt;line-height:10.0pt"><span style="font-family:AdvPA183,serif;font-size:10.0pt">METHODS</span></p>
<p style="top:394.2pt;left:35.9pt;line-height:10.0pt"><span style="font-family:AdvPA183,serif;font-size:10.0pt">Article Identification and Selection</span></p>
<p style="top:415.0pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">A systematic review of articles, using the PRISMA (Pre-</span></p>
<p style="top:426.2pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">ferred Reporting Items for Systematic Meta-Analyses)</span></p>
<p style="top:437.4pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">guidelines, on the efficacy of vitamin C in promoting colla-</span></p>
<p style="top:448.6pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">gen synthesis, reducing inflammation, and improving bone/</span></p>
<p style="top:459.9pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">ligament/tendon healing after musculoskeletal injuries was</span></p>
<p style="top:471.1pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">performed using the Cochrane Database of Systematic</span></p>
<p style="top:482.3pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">Reviews, the Cochrane Central Register of Controlled</span></p>
<p style="top:493.5pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">Trials, PubMed (1980-2017), MEDLINE (1980-2017), and</span></p>
<p style="top:504.8pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">Embase (1980-2017); the queries were performed in</span></p>
<p style="top:516.0pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">November 2017. Registration of this systematic review was</span></p>
<p style="top:527.2pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">performed in January 2018 using the PROSPERO interna-</span></p>
<p style="top:538.4pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">tional</span></p>
<p style="top:538.4pt;left:69.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">prospective</span></p>
<p style="top:538.4pt;left:129.2pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">register</span></p>
<p style="top:538.4pt;left:172.3pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">of</span></p>
<p style="top:538.4pt;left:188.1pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">systematic</span></p>
<p style="top:538.4pt;left:244.2pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">reviews</span></p>
<p style="top:549.7pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">(CRD42018086378). The search terms utilized were</span></p>
<p style="top:560.9pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">&#x201c;vitamin C&#x201d; OR &#x201c;ascorbic acid&#x201d; AND &#x201c;musculoskeletal</span></p>
<p style="top:572.1pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">injury&#x201d;; &#x201c;vitamin C&#x201d; OR &#x201c;ascorbic acid&#x201d; AND &#x201c;collagen</span></p>
<p style="top:583.3pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">cross-linking&#x201d;; &#x201c;vitamin C&#x201d; OR &#x201c;ascorbic acid&#x201d; AND</span></p>
<p style="top:594.6pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">&#x201c;orthopaedics&#x201d;; &#x201c;vitamin C&#x201d; OR &#x201c;ascorbic acid&#x201d; AND &#x201c;bone</span></p>
<p style="top:605.8pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">healing&#x201d;; &#x201c;vitamin C&#x201d; OR &#x201c;ascorbic acid&#x201d; AND &#x201c;ligament</span></p>
<p style="top:617.0pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">healing&#x201d;; &#x201c;vitamin C&#x201d; OR &#x201c;ascorbic acid&#x201d; AND &#x201c;tendon</span></p>
<p style="top:71.0pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">healing&#x201d;; and &#x201c;vitamin C&#x201d; OR &#x201c;ascorbic acid&#x201d; AND</span></p>
<p style="top:81.9pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">&#x201c;postoperative recovery.&#x201d;</span></p>
<p style="top:92.9pt;left:316.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">The inclusion criteria consisted of English-language</span></p>
<p style="top:103.9pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">studies and both animal and human studies on vitamin C</span></p>
<p style="top:114.8pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">supplementation after musculoskeletal injuries specific to</span></p>
<p style="top:125.8pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">collagen cross-linking, collagen synthesis, and biologic</span></p>
<p style="top:136.8pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">healing of the bone, ligament, and tendon. Exclusion</span></p>
<p style="top:147.7pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">criteria were vitamin C supplementation specific to</span></p>
<p style="top:158.7pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">nonmusculoskeletal-related injuries or surgery, healthy/</span></p>
<p style="top:169.6pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">noninjured populations, scurvy, vitamin C deficiency, effect</span></p>
<p style="top:180.6pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">of vitamin C on mesenchymal stem cells, genetic studies,</span></p>
<p style="top:191.5pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">cellular studies, epidemiological studies, dietary intake</span></p>
<p style="top:202.5pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">without vitamin C supplementation, editorial articles,</span></p>
<p style="top:213.5pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">review articles, case reports (level 5 evidence), and surveys.</span></p>
<p style="top:224.4pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">Two investigators (N.N.D., Z.S.A.) independently reviewed</span></p>
<p style="top:235.4pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">the abstracts from all identified articles. If necessary, full-</span></p>
<p style="top:246.3pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">text articles were obtained for a review to allow for further</span></p>
<p style="top:257.3pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">application of inclusion and exclusion criteria. Addition-</span></p>
<p style="top:268.3pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">ally, reference lists from the included studies were</span></p>
<p style="top:279.2pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">reviewed and reconciled to verify that all eligible articles</span></p>
<p style="top:290.2pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">were considered.</span></p>
<p style="top:314.6pt;left:306.4pt;line-height:10.0pt"><span style="font-family:AdvPA183,serif;font-size:10.0pt">Data Collection</span></p>
<p style="top:335.4pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">Both animal and human studies were collected. These find-</span></p>
<p style="top:346.3pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">ings included experimental focus, abnormality, animal</span></p>
<p style="top:357.2pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">model type, collagen type (ie, bone, ligament, tendon),</span></p>
<p style="top:368.2pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">treatments, postoperative restrictions, route of vitamin C</span></p>
<p style="top:379.2pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">administration, and vitamin C dosage (including frequency</span></p>
<p style="top:390.1pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">and duration). The level of evidence of all available clinical</span></p>
<p style="top:401.1pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">studies was assigned according to the classification as spec-</span></p>
<p style="top:412.1pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">ified by Wright et al.</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">38</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">Patient demographics, supplemen-</span></p>
<p style="top:423.0pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">tation dosage, treatment details, follow-up, and subjective</span></p>
<p style="top:434.0pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">and objective patient outcomes were recorded for all clinical</span></p>
<p style="top:445.0pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">studies. For continuous variables (age, outcome scores, etc),</span></p>
<p style="top:455.9pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">the mean and range were obtained if reported.</span></p>
<p style="top:490.0pt;left:306.4pt;line-height:10.0pt"><span style="font-family:AdvPA183,serif;font-size:10.0pt">RESULTS</span></p>
<p style="top:510.7pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">The literature search identified 286 studies from the afore-</span></p>
<p style="top:521.7pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">mentioned databases. After duplicates were removed, 264</span></p>
<p style="top:532.6pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">articles were screened, and 10 articles met the inclusion</span></p>
<p style="top:543.6pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">criteria (Figure 1). There were 7 studies that evaluated the</span></p>
<p style="top:554.5pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">effects of vitamin C supplementation in animal models: 4</span></p>
<p style="top:565.5pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">after bone fractures (nonoperative treatment), 2 after ten-</span></p>
<p style="top:576.5pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">don ruptures (nonoperative and surgical treatment), and 1</span></p>
<p style="top:587.4pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">after anterior cruciate ligament (ACL) reconstruction</span></p>
<p style="top:598.4pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">(ACLR) (Table 1). Six of the animal studies used a rat</span></p>
<p style="top:609.3pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">model, and 1 study used a chicken model. There were 3</span></p>
<p style="top:620.3pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">studies</span></p>
<p style="top:620.3pt;left:346.5pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">that</span></p>
<p style="top:620.3pt;left:373.0pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">evaluated</span></p>
<p style="top:620.3pt;left:425.0pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">the</span></p>
<p style="top:620.3pt;left:447.2pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">effects</span></p>
<p style="top:620.3pt;left:484.1pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">of</span></p>
<p style="top:620.3pt;left:499.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">vitamin</span></p>
<p style="top:620.3pt;left:542.7pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">C</span></p>
<p style="top:645.7pt;left:47.8pt;line-height:5.3pt"><span style="font-family:AdvP4C4E74,serif;font-size:5.3pt">k</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">Address correspondence to Robert F. LaPrade, MD, PhD, The Steadman Clinic, 181 West Meadow Drive, Suite 400, Vail, CO 81657, USA (email:</span></p>
<p style="top:656.3pt;left:35.9pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">drlaprade@sprivail.org).</span></p>
<p style="top:665.2pt;left:47.8pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">*The Steadman Clinic, Vail, Colorado, USA.</span></p>
<p style="top:672.6pt;left:48.1pt;line-height:5.3pt"><span style="font-family:AdvPA183,serif;font-size:5.3pt">&#x2020;</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">Steadman Philippon Research Institute, Vail, Colorado, USA.</span></p>
<p style="top:681.6pt;left:48.1pt;line-height:5.3pt"><span style="font-family:AdvPA183,serif;font-size:5.3pt">&#x2021;</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">Oslo University Hospital, Oslo, Norway.</span></p>
<p style="top:690.5pt;left:48.1pt;line-height:5.3pt"><span style="font-family:AdvPA183,serif;font-size:5.3pt">&#xa7;</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">OSTRC, Norwegian School of Sports Science, Oslo, Norway.</span></p>
<p style="top:701.1pt;left:47.8pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">One or more of the authors has declared the following potential conflict of interest or source of funding: R.F.L. is a consultant for and receives royalties</span></p>
<p style="top:710.1pt;left:35.9pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">from Arthrex, Ossur, and Smith &amp; Nephew. AOSSM checks author disclosures against the Open Payments Database (OPD). AOSSM has not conducted an</span></p>
<p style="top:719.0pt;left:35.9pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">independent investigation on the OPD and disclaims any liability or responsibility relating thereto.</span></p>
<p style="top:35.2pt;left:35.9pt;line-height:8.5pt"><span style="font-family:AdvPAEBA,serif;font-size:8.5pt">2</span></p>
<p style="top:35.2pt;left:50.7pt;line-height:8.5pt"><span style="font-family:AdvPAEB9,serif;font-size:8.5pt">DePhillipo et al</span></p>
<p style="top:35.2pt;left:374.3pt;line-height:8.5pt"><span style="font-family:AdvPAEB9,serif;font-size:8.5pt">The Orthopaedic Journal of Sports Medicine</span></p>


<p style="top:505.1pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">supplementation in human models: 1 after ACLR and 2</span></p>
<p style="top:516.0pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">after bone fractures (nonoperative and surgical treatment).</span></p>
<p style="top:527.0pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">Two of the clinical studies were level 1 evidence, while 1</span></p>
<p style="top:538.0pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">study was level 2 evidence.</span></p>
<p style="top:565.6pt;left:35.9pt;line-height:10.0pt"><span style="font-family:AdvPA183,serif;font-size:10.0pt">Preclinical Studies</span></p>
<p style="top:586.3pt;left:47.8pt;line-height:9.0pt"><span style="font-family:AdvPAEB9,serif;font-size:9.0pt">Vitamin C Dosage.</span><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> Four studies determined vitamin C</span></p>
<p style="top:597.3pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">dosage as a function of animal weight, ranging from 0.5 mg/</span></p>
<p style="top:608.2pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">kg to 500 mg/kg.</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">5,15,33,41</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">The remaining 3 studies applied</span></p>
<p style="top:619.2pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">standard doses between 0.005 mg and 150 mg.</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">10,19,25</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">The</span></p>
<p style="top:630.1pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">delivery of vitamin C varied, including intraperitoneally</span></p>
<p style="top:641.1pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">(n</span><span style="font-family:AdvP4C4E74,serif;font-size:9.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> 4),</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">5,15,25,33</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">locally (n</span><span style="font-family:AdvP4C4E74,serif;font-size:9.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> 1),</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">19</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">intramuscularly (n</span><span style="font-family:AdvP4C4E74,serif;font-size:9.0pt"> &#xbc;</span></p>
<p style="top:652.1pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">1),</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">41</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">or by intraoperative irrigation (n</span><span style="font-family:AdvP4C4E74,serif;font-size:9.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> 1).</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">10</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">The interven-</span></p>
<p style="top:663.0pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">tion was initiated on postinjury day 0 in all preclinical stud-</span></p>
<p style="top:674.0pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">ies (n</span><span style="font-family:AdvP4C4E74,serif;font-size:9.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> 7). The frequency of vitamin C dosage varied</span></p>
<p style="top:684.9pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">between once at the time of injury to once per day until the</span></p>
<p style="top:695.9pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">end of the trial. The duration of individual trials ranged</span></p>
<p style="top:706.9pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">from 3 days to 6 weeks. Four studies allowed free access</span></p>
<p style="top:717.8pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">to standard diet and water,</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">5,25,33,41</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">1 study provided a diet</span></p>
<p style="top:505.1pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">that did not contain vitamin C,</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">15</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">and 2 studies did not</span></p>
<p style="top:516.3pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">report food and water restrictions.</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">10,19</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">Five studies allowed</span></p>
<p style="top:527.6pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">animals to move freely without immobilization after the pro-</span></p>
<p style="top:538.8pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">cedure,</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">10,15,25,33,41</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">1 study immobilized the injured limb,</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">19</span></sup></p>
<p style="top:550.0pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">and 1 study did not report on immobilization</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">5</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">(Table 2).</span></p>
<p style="top:560.9pt;left:318.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB9,serif;font-size:9.0pt">Efficacy of Vitamin C on Collagen Synthesis and Tissue</span></p>
<p style="top:571.9pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB9,serif;font-size:9.0pt">Healing.</span><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> Overall, the preclinical studies supported the use</span></p>
<p style="top:582.9pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">of vitamin C for tendon, bone, and ligament graft healing.</span></p>
<p style="top:594.1pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">Three of the 4 studies evaluating the effects of vitamin C on</span></p>
<p style="top:605.3pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">fracture healing reported an increase or acceleration in col-</span></p>
<p style="top:616.6pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">lagen synthesis when compared with control groups.</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">5,33,41</span></sup></p>
<p style="top:627.8pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">One study reported that there were no significant histolog-</span></p>
<p style="top:639.0pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">ical or histomorphological score differences between the</span></p>
<p style="top:650.2pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">vitamin C and control groups for fracture healing.</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">15</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">Both</span></p>
<p style="top:661.5pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">studies evaluating tendon healing after ruptures reported</span></p>
<p style="top:672.7pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">improved structural quality with vitamin C supplementa-</span></p>
<p style="top:683.9pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">tion.</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">19,25</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">Omeroglu et al</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">25</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">reported that there was a signif-</span></p>
<p style="top:695.1pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">icant increase in type I collagen formation and a higher rate</span></p>
<p style="top:706.4pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">in active fibroblasts in low-dose vitamin C groups. Hung</span></p>
<p style="top:717.6pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">et al</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">19</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">reported similar structural integrity in tendons, as</span></p>
<img style="position:absolute;transform:matrix(.54850378,0,-0,.5484159,-100.89136,-114.54132)" src="data:image/jpeg;base64,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">
<p style="top:469.2pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPA189,serif;font-size:9.0pt">Figure 1.</span><span style="font-family:AdvPA183,serif;font-size:9.0pt"> PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flowchart showing the selection criteria</span></p>
<p style="top:480.2pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPA183,serif;font-size:9.0pt">used to identify studies with the search strategy.</span></p>
<p style="top:35.2pt;left:35.9pt;line-height:8.5pt"><span style="font-family:AdvPAEB9,serif;font-size:8.5pt">The Orthopaedic Journal of Sports Medicine</span></p>
<p style="top:35.2pt;left:329.8pt;line-height:8.5pt"><span style="font-family:AdvPAEB9,serif;font-size:8.5pt">Efficacy of Vitamin C After Musculoskeletal Injuries</span></p>
<p style="top:35.2pt;left:544.3pt;line-height:8.5pt"><span style="font-family:AdvPAEBA,serif;font-size:8.5pt">3</span></p>


<p style="top:530.0pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">vitamin C significantly reduced the fibrotic size and peri-</span></p>
<p style="top:541.1pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">tendinous adhesion. However, the authors did not report on</span></p>
<p style="top:552.2pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">tendinous collagen composition.</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">19</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">Fu et al</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">10</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">reported that</span></p>
<p style="top:563.3pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">low-dose vitamin C restored anteroposterior knee stability</span></p>
<p style="top:574.3pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">and significantly reduced graft deterioration after ACLR</span></p>
<p style="top:585.4pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">compared with the control group after 6 weeks; however,</span></p>
<p style="top:596.4pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">there were no significant differences in long-term outcomes</span></p>
<p style="top:607.5pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">(42 weeks) or ACL graft incorporation between groups. All</span></p>
<p style="top:618.5pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">of the studies evaluating the role of vitamin C as an anti-</span></p>
<p style="top:629.6pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">oxidant and collagen synthesizer (n</span><span style="font-family:AdvP4C4E74,serif;font-size:9.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> 3) suggested that</span></p>
<p style="top:640.7pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">vitamin C positively influences bone, tendon, and graft</span></p>
<p style="top:651.8pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">healing by antagonizing oxidative stress.</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">5,10,19</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">No adverse</span></p>
<p style="top:662.8pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">effects were reported in any preclinical study (n</span><span style="font-family:AdvP4C4E74,serif;font-size:9.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> 7).</span></p>
<p style="top:673.8pt;left:47.8pt;line-height:9.0pt"><span style="font-family:AdvPAEB9,serif;font-size:9.0pt">Efficacy of Vitamin C on the Reduction of Oxidative</span></p>
<p style="top:684.7pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB9,serif;font-size:9.0pt">Stress Parameters.</span><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> Three preclinical studies</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">5,10,19</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">evalu-</span></p>
<p style="top:695.7pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">ated oxidative stress after vitamin C supplementation. All</span></p>
<p style="top:706.8pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">3 preclinical studies reported that vitamin C was effective</span></p>
<p style="top:717.8pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">in reducing oxidative stress after injuries by decreasing</span></p>
<p style="top:530.0pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">endogenous or exogenous ROS, signified by an improved</span></p>
<p style="top:541.0pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">tissue composition in ligaments, tendons, and bone. How-</span></p>
<p style="top:552.0pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">ever, only 1 of the 3 studies reported vitamin C as an antag-</span></p>
<p style="top:562.9pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">onist for oxidative stress after 2 weeks.</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">19</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">Furthermore, 1</span></p>
<p style="top:573.9pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">clinical study evaluated oxidative stress and muscle recov-</span></p>
<p style="top:584.9pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">ery after vitamin C and E supplementation after ACLR.</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">2</span></sup></p>
<p style="top:595.8pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">The authors reported that vitamin C and E supplementa-</span></p>
<p style="top:606.8pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">tion had no significant effects on oxidative stress para-</span></p>
<p style="top:617.8pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">meters compared with controls after ACLR.</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">2</span></sup></p>
<p style="top:642.3pt;left:306.4pt;line-height:10.0pt"><span style="font-family:AdvPA183,serif;font-size:10.0pt">Clinical Studies</span></p>
<p style="top:663.0pt;left:318.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB9,serif;font-size:9.0pt">Patient Demographics and Vitamin C Dosage.</span><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> The</span></p>
<p style="top:674.0pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">patient demographics, study design, and experimental</span></p>
<p style="top:684.9pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">focus of all clinical studies are reported in Table 3. Of the</span></p>
<p style="top:695.9pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">3 clinical studies, 2 studies evaluated a combined supple-</span></p>
<p style="top:706.9pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">ment of vitamin C and other antioxidants,</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">2,32</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">while 1 study</span></p>
<p style="top:717.8pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">evaluated exclusively the effects of vitamin C.</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">6</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">The dosage</span></p>
<p style="top:71.5pt;left:273.0pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">TABLE 1</span></p>
<p style="top:82.5pt;left:137.1pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">Preclinical Studies: Demographics, Study Design, and Experimental Focus</span></p>
<p style="top:111.3pt;left:35.9pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Study</span></p>
<p style="top:101.3pt;left:116.4pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Study Design</span></p>
<p style="top:111.3pt;left:106.1pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(Level of Evidence)</span></p>
<p style="top:111.3pt;left:201.7pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Participants</span></p>
<p style="top:111.3pt;left:281.6pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Abnormality</span></p>
<p style="top:111.3pt;left:367.5pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Experimental Groups</span></p>
<p style="top:101.3pt;left:488.0pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Experimental</span></p>
<p style="top:111.3pt;left:502.6pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Focus</span></p>
<p style="top:129.5pt;left:35.9pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Omeroglu et al</span><sup><span style="font-family:AdvPAEB8,serif;font-size:5.6pt">25</span></sup></p>
<p style="top:139.5pt;left:44.8pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(2009)</span></p>
<p style="top:129.5pt;left:106.1pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Randomized</span></p>
<p style="top:139.5pt;left:115.1pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">controlled</span></p>
<p style="top:149.5pt;left:115.1pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">trial (level 1)</span></p>
<p style="top:129.5pt;left:182.4pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Female, nonpregnant,</span></p>
<p style="top:139.5pt;left:191.4pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">albino Wistar rats</span></p>
<p style="top:149.5pt;left:191.4pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(N</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 42)</span></p>
<p style="top:129.5pt;left:272.4pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Achilles tendon</span></p>
<p style="top:139.5pt;left:281.4pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">rupture</span></p>
<p style="top:129.5pt;left:343.3pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(1) Vitamin C (n</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 21) and (2)</span></p>
<p style="top:139.5pt;left:352.2pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">control (n</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 21) with subgroups</span></p>
<p style="top:149.5pt;left:352.2pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(3rd day, 10th day, and 21st day</span></p>
<p style="top:159.5pt;left:352.2pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">[n</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 7 each])</span></p>
<p style="top:129.5pt;left:477.5pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Tendon healing</span></p>
<p style="top:169.4pt;left:35.9pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Sarisozen et al</span><sup><span style="font-family:AdvPAEB8,serif;font-size:5.6pt">33</span></sup></p>
<p style="top:179.4pt;left:44.8pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(2002)</span></p>
<p style="top:169.4pt;left:106.1pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Randomized</span></p>
<p style="top:179.4pt;left:115.1pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">controlled trial</span></p>
<p style="top:189.3pt;left:115.1pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(level 1)</span></p>
<p style="top:169.4pt;left:182.4pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Sprague-Dawley rats</span></p>
<p style="top:179.4pt;left:191.4pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(N</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 48)</span></p>
<p style="top:169.4pt;left:272.4pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Tibial fracture</span></p>
<p style="top:169.4pt;left:343.3pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(1) Vitamin E only (n</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 12), (2)</span></p>
<p style="top:179.4pt;left:352.2pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">vitamin C only (n</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 12), (3)</span></p>
<p style="top:189.3pt;left:352.2pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">vitamin C and E (n</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 12), and</span></p>
<p style="top:199.3pt;left:352.2pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(4) no treatment (n</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 12)</span></p>
<p style="top:169.4pt;left:477.5pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Bone healing</span></p>
<p style="top:209.2pt;left:35.9pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Hung et al</span><sup><span style="font-family:AdvPAEB8,serif;font-size:5.6pt">19</span></sup></p>
<p style="top:219.2pt;left:44.8pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(2013)</span></p>
<p style="top:209.2pt;left:106.1pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Controlled trial</span></p>
<p style="top:219.2pt;left:115.1pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(level 2)</span></p>
<p style="top:209.2pt;left:182.4pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Female Kamei</span></p>
<p style="top:219.2pt;left:191.4pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">chickens (N</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 57)</span></p>
<p style="top:209.2pt;left:272.4pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Flexor digitorum</span></p>
<p style="top:219.2pt;left:281.4pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">profundus</span></p>
<p style="top:229.2pt;left:281.4pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">tendon tear</span></p>
<p style="top:209.2pt;left:343.3pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Part 1: (1) Operated (n</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 9) with</span></p>
<p style="top:219.2pt;left:352.2pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">subgroups (day 0, 2 weeks, and</span></p>
<p style="top:229.2pt;left:352.2pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">6 weeks [n</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 3 each]) and</span></p>
<p style="top:239.2pt;left:352.2pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(2) sham (n</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 3) with subgroups</span></p>
<p style="top:249.1pt;left:352.2pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(day 0, 2 weeks, and 6 weeks</span></p>
<p style="top:259.1pt;left:352.2pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">[n</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 1 each])</span></p>
<p style="top:269.0pt;left:343.3pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Part 2: (1) 5 mg/mL of vitamin C</span></p>
<p style="top:279.0pt;left:353.3pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(n</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 12), (2) 50 mg/mL of</span></p>
<p style="top:288.9pt;left:353.3pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">vitamin C (n</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 12), and</span></p>
<p style="top:298.9pt;left:353.3pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(3) control (n</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 12)</span></p>
<p style="top:209.2pt;left:477.5pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Reduction of</span></p>
<p style="top:219.2pt;left:486.5pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">tendon adhesion</span></p>
<p style="top:229.2pt;left:486.5pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">by antagonizing</span></p>
<p style="top:239.2pt;left:486.5pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">oxidative stress</span></p>
<p style="top:308.9pt;left:35.9pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Giordano et al</span><sup><span style="font-family:AdvPAEB8,serif;font-size:5.6pt">15</span></sup></p>
<p style="top:318.8pt;left:44.8pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(2012)</span></p>
<p style="top:308.9pt;left:106.1pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Controlled trial</span></p>
<p style="top:318.8pt;left:115.1pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(level 2)</span></p>
<p style="top:308.9pt;left:182.4pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Male Wistar rats</span></p>
<p style="top:318.8pt;left:191.4pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(N</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 30)</span></p>
<p style="top:308.9pt;left:272.4pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Tibial fracture</span></p>
<p style="top:308.9pt;left:343.3pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(1) Vitamin C (n</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 15) and</span></p>
<p style="top:318.8pt;left:352.2pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(2) control (n</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 15)</span></p>
<p style="top:308.9pt;left:477.5pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Bone healing and</span></p>
<p style="top:318.8pt;left:486.5pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">effect on</span></p>
<p style="top:328.8pt;left:486.5pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">osteogenesis</span></p>
<p style="top:338.8pt;left:35.9pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Duygulu et al</span><sup><span style="font-family:AdvPAEB8,serif;font-size:5.6pt">5</span></sup></p>
<p style="top:348.7pt;left:44.8pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(2007)</span></p>
<p style="top:338.8pt;left:106.1pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Randomized</span></p>
<p style="top:348.7pt;left:115.1pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">controlled trial</span></p>
<p style="top:358.7pt;left:115.1pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(level 1)</span></p>
<p style="top:338.8pt;left:182.4pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Male, albino Wistar</span></p>
<p style="top:348.7pt;left:191.4pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">rats (N</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 50)</span></p>
<p style="top:338.8pt;left:272.4pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Radial and ulnar</span></p>
<p style="top:348.7pt;left:281.4pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">fracture</span></p>
<p style="top:338.8pt;left:343.3pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(1) Control (n</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 10), (2) zymosan</span></p>
<p style="top:348.7pt;left:352.2pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">only (n</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 10), (3) zymosan</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xfe;</span></p>
<p style="top:358.7pt;left:352.2pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">DMSO (n</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 10), (4) zymosan</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xfe;</span></p>
<p style="top:368.6pt;left:352.2pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">EGb 761 (n</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 10), and (5)</span></p>
<p style="top:378.6pt;left:352.2pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">zymosan</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xfe;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> vitamin C (n</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 10)</span></p>
<p style="top:338.8pt;left:477.5pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Effect of oxidative</span></p>
<p style="top:348.7pt;left:486.5pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">stress and</span></p>
<p style="top:358.7pt;left:486.5pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">protective effect</span></p>
<p style="top:368.6pt;left:486.5pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">of antioxidants</span></p>
<p style="top:378.6pt;left:486.5pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">on bone healing</span></p>
<p style="top:388.5pt;left:35.9pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Yilmaz et al</span><sup><span style="font-family:AdvPAEB8,serif;font-size:5.6pt">41</span></sup></p>
<p style="top:398.5pt;left:44.8pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(2001)</span></p>
<p style="top:388.5pt;left:106.1pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Randomized</span></p>
<p style="top:398.5pt;left:115.1pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">controlled trial</span></p>
<p style="top:408.5pt;left:115.1pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(level 1)</span></p>
<p style="top:388.5pt;left:182.4pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Albino Wistar rats</span></p>
<p style="top:398.5pt;left:191.4pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(N</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 16)</span></p>
<p style="top:388.5pt;left:272.4pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Tibial fracture</span></p>
<p style="top:388.5pt;left:343.3pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(1) Control (n</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 8) and (2) vitamin</span></p>
<p style="top:398.5pt;left:352.2pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">C (n</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 8)</span></p>
<p style="top:388.5pt;left:477.5pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Bone healing</span></p>
<p style="top:418.5pt;left:35.9pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Fu et al</span><sup><span style="font-family:AdvPAEB8,serif;font-size:5.6pt">10</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(2013)</span></p>
<p style="top:418.5pt;left:106.1pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Controlled trial</span></p>
<p style="top:428.4pt;left:115.1pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(level 2)</span></p>
<p style="top:418.5pt;left:182.4pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Male Sprague-Dawley</span></p>
<p style="top:428.4pt;left:191.4pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">rats (N</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 114)</span></p>
<p style="top:418.5pt;left:272.4pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Anterior cruciate</span></p>
<p style="top:428.4pt;left:281.4pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">ligament tear</span></p>
<p style="top:418.5pt;left:343.3pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Part 1: (1) Control (n</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 26), (2)</span></p>
<p style="top:428.4pt;left:352.2pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">3 mg/mL of vitamin C (n</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 26),</span></p>
<p style="top:438.4pt;left:352.2pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(3) 10 mg/mL of vitamin C</span></p>
<p style="top:448.4pt;left:352.2pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(n</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 26), and (4) 30 mg/mL of</span></p>
<p style="top:458.3pt;left:352.2pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">vitamin C (n</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 26) with</span></p>
<p style="top:468.3pt;left:352.2pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">subgroups (day 1, day 2, day 3,</span></p>
<p style="top:478.2pt;left:352.2pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">and week 6 [n</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 4 each])</span></p>
<p style="top:488.2pt;left:343.3pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Part 2: (1) Sham (n</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 10) and (2)</span></p>
<p style="top:498.2pt;left:353.3pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">operated (n</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 10)</span></p>
<p style="top:418.5pt;left:477.5pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Ligament graft</span></p>
<p style="top:428.4pt;left:486.5pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">healing and</span></p>
<p style="top:438.4pt;left:486.5pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">reduction of</span></p>
<p style="top:448.4pt;left:486.5pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">C-reactive</span></p>
<p style="top:458.3pt;left:486.5pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">protein plasma</span></p>
<p style="top:468.3pt;left:486.5pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">levels</span></p>
<p style="top:35.2pt;left:35.9pt;line-height:8.5pt"><span style="font-family:AdvPAEBA,serif;font-size:8.5pt">4</span></p>
<p style="top:35.2pt;left:50.7pt;line-height:8.5pt"><span style="font-family:AdvPAEB9,serif;font-size:8.5pt">DePhillipo et al</span></p>
<p style="top:35.2pt;left:374.3pt;line-height:8.5pt"><span style="font-family:AdvPAEB9,serif;font-size:8.5pt">The Orthopaedic Journal of Sports Medicine</span></p>


<p style="top:71.5pt;left:273.0pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">TABLE 2</span></p>
<p style="top:82.5pt;left:141.8pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">Preclinical Studies: Treatment Protocols After Musculoskeletal Injuries</span><sup><span style="font-family:AdvPAEB9,serif;font-size:6.3pt">a</span></sup></p>
<p style="top:108.9pt;left:35.9pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Study</span></p>
<p style="top:101.0pt;left:76.2pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Treatment and</span></p>
<p style="top:108.9pt;left:80.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Restrictions</span></p>
<p style="top:101.0pt;left:141.3pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Route of</span></p>
<p style="top:108.9pt;left:139.7pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Exposure</span></p>
<p style="top:108.9pt;left:193.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Dosage</span></p>
<p style="top:108.9pt;left:237.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Frequency</span></p>
<p style="top:108.9pt;left:287.7pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Duration</span></p>
<p style="top:108.9pt;left:337.0pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Conditions</span></p>
<p style="top:108.9pt;left:411.9pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Results</span></p>
<p style="top:108.9pt;left:493.2pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Conclusion</span></p>
<p style="top:125.2pt;left:35.9pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Omeroglu</span></p>
<p style="top:133.2pt;left:44.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">et al</span><sup><span style="font-family:AdvPAEB8,serif;font-size:4.2pt">25</span></sup></p>
<p style="top:141.1pt;left:44.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">(2009)</span></p>
<p style="top:125.2pt;left:69.1pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">None;</span></p>
<p style="top:133.2pt;left:78.0pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">weightbearing</span></p>
<p style="top:141.1pt;left:78.0pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">without</span></p>
<p style="top:149.1pt;left:78.0pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">immobilization</span></p>
<p style="top:125.2pt;left:129.0pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Intraperitoneally 150 mg vitamin</span></p>
<p style="top:133.2pt;left:189.5pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">C (1.5 mL)</span></p>
<p style="top:125.2pt;left:230.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Once on day of</span></p>
<p style="top:133.2pt;left:239.5pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">injury and</span></p>
<p style="top:141.1pt;left:239.5pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">then once</span></p>
<p style="top:149.1pt;left:239.5pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">every 2 days</span></p>
<p style="top:125.2pt;left:277.3pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">3 days, 10 days,</span></p>
<p style="top:133.2pt;left:286.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">and 21 days</span></p>
<p style="top:125.2pt;left:327.2pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Allowed to move</span></p>
<p style="top:133.2pt;left:336.1pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">freely in cages</span></p>
<p style="top:141.1pt;left:336.1pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">with free</span></p>
<p style="top:149.1pt;left:336.1pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">access to food</span></p>
<p style="top:157.0pt;left:336.1pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">and water</span></p>
<p style="top:125.2pt;left:380.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Significant difference in type I</span></p>
<p style="top:133.2pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">collagen production on</span></p>
<p style="top:141.1pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">10th day, mean collagen</span></p>
<p style="top:149.1pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">fiber diameter and active</span></p>
<p style="top:157.0pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">fibroblasts higher in</span></p>
<p style="top:165.0pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">vitamin C group, and more</span></p>
<p style="top:173.0pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">evident angiogenesis on</span></p>
<p style="top:180.9pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">3rd day</span></p>
<p style="top:125.2pt;left:467.7pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Low dose of vitamin C</span></p>
<p style="top:133.2pt;left:476.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">irrigation may be of</span></p>
<p style="top:141.1pt;left:476.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">potential use to promote</span></p>
<p style="top:149.1pt;left:476.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">healing</span></p>
<p style="top:188.9pt;left:35.9pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Sarisozen</span></p>
<p style="top:196.9pt;left:44.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">et al</span><sup><span style="font-family:AdvPAEB8,serif;font-size:4.2pt">33</span></sup></p>
<p style="top:204.9pt;left:44.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">(2002)</span></p>
<p style="top:188.9pt;left:69.1pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">None;</span></p>
<p style="top:196.9pt;left:78.0pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">weightbearing</span></p>
<p style="top:204.9pt;left:78.0pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">without</span></p>
<p style="top:212.8pt;left:78.0pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">immobilization</span></p>
<p style="top:188.9pt;left:129.0pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Intraperitoneally 200 mg/kg</span></p>
<p style="top:196.9pt;left:189.5pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">vitamin C</span></p>
<p style="top:188.9pt;left:230.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Once per day</span></p>
<p style="top:196.9pt;left:239.5pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">for 3 days</span></p>
<p style="top:204.9pt;left:239.5pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">and then</span></p>
<p style="top:212.8pt;left:239.5pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">3 times per</span></p>
<p style="top:220.8pt;left:239.5pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">week</span></p>
<p style="top:188.9pt;left:277.3pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">14 days and</span></p>
<p style="top:196.9pt;left:286.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">21 days</span></p>
<p style="top:188.9pt;left:327.2pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Free access to</span></p>
<p style="top:196.9pt;left:336.1pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">food and water</span></p>
<p style="top:188.9pt;left:380.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Vitamin C group had</span></p>
<p style="top:196.9pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">accelerated bone matrix</span></p>
<p style="top:204.9pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">mineralization and</span></p>
<p style="top:212.8pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">increased amount of</span></p>
<p style="top:220.8pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">collagen</span></p>
<p style="top:188.9pt;left:467.7pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Vitamin C supplementation</span></p>
<p style="top:196.9pt;left:476.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">accelerated fracture</span></p>
<p style="top:204.9pt;left:476.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">healing</span></p>
<p style="top:228.8pt;left:35.9pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Hung</span></p>
<p style="top:236.7pt;left:44.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">et al</span><sup><span style="font-family:AdvPAEB8,serif;font-size:4.2pt">19</span></sup></p>
<p style="top:244.7pt;left:44.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">(2013)</span></p>
<p style="top:228.8pt;left:69.1pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Tendon repair;</span></p>
<p style="top:236.7pt;left:78.0pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">immobilization</span></p>
<p style="top:244.7pt;left:78.0pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">for 2 weeks</span></p>
<p style="top:228.8pt;left:129.0pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Local injection</span></p>
<p style="top:228.8pt;left:180.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">5 mg/mL or</span></p>
<p style="top:236.7pt;left:189.5pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">50 mg/mL</span></p>
<p style="top:244.7pt;left:189.5pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">vitamin C</span></p>
<p style="top:252.7pt;left:189.5pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">(50</span><span style="font-family:AdvPi1,serif;font-size:6.0pt"> m</span><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">L total</span></p>
<p style="top:260.7pt;left:189.5pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">volume)</span></p>
<p style="top:228.8pt;left:230.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Once</span></p>
<p style="top:228.8pt;left:277.3pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">2 weeks and</span></p>
<p style="top:236.7pt;left:286.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">6 weeks</span></p>
<p style="top:228.8pt;left:327.2pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">N/A</span></p>
<p style="top:228.8pt;left:380.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">No significant difference at</span></p>
<p style="top:236.7pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">2 weeks between groups,</span></p>
<p style="top:244.7pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">significant improvement</span></p>
<p style="top:252.7pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">in gliding resistance at 6</span></p>
<p style="top:260.7pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">weeks in vitamin C group,</span></p>
<p style="top:268.6pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">5 mg/mL of vitamin C had</span></p>
<p style="top:276.6pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">significant reduction in</span></p>
<p style="top:284.6pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">fibrotic size at 6 weeks</span></p>
<p style="top:292.5pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">compared with control</span></p>
<p style="top:300.5pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">group, and less</span></p>
<p style="top:308.5pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">peritendinous adhesion in</span></p>
<p style="top:316.4pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">vitamin C group</span></p>
<p style="top:228.8pt;left:467.7pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Local injection of vitamin C</span></p>
<p style="top:236.7pt;left:476.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">solution can reduce extent</span></p>
<p style="top:244.7pt;left:476.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">of tendon adhesion after</span></p>
<p style="top:252.7pt;left:476.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">tendon repair</span></p>
<p style="top:324.4pt;left:35.9pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Giordano</span></p>
<p style="top:332.4pt;left:44.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">et al</span><sup><span style="font-family:AdvPAEB8,serif;font-size:4.2pt">15</span></sup></p>
<p style="top:340.4pt;left:44.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">(2012)</span></p>
<p style="top:324.4pt;left:69.1pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">None;</span></p>
<p style="top:332.4pt;left:78.0pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">weightbearing</span></p>
<p style="top:340.4pt;left:78.0pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">without</span></p>
<p style="top:348.3pt;left:78.0pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">immobilization</span></p>
<p style="top:324.4pt;left:129.0pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Intraperitoneally 200 mg/kg</span></p>
<p style="top:332.4pt;left:189.5pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">vitamin C</span></p>
<p style="top:324.4pt;left:230.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Once per day</span></p>
<p style="top:324.4pt;left:277.3pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">2 weeks,</span></p>
<p style="top:332.4pt;left:286.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">4 weeks,</span></p>
<p style="top:340.4pt;left:286.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">and 6 weeks</span></p>
<p style="top:324.4pt;left:327.2pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Caged with access</span></p>
<p style="top:332.4pt;left:336.1pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">to water and</span></p>
<p style="top:340.4pt;left:336.1pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">standard feed</span></p>
<p style="top:348.3pt;left:336.1pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">ad libitum</span></p>
<p style="top:356.3pt;left:336.1pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">containing no</span></p>
<p style="top:364.3pt;left:336.1pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">vitamin C</span></p>
<p style="top:324.4pt;left:380.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">No significant histological</span></p>
<p style="top:332.4pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">or histomorphological</span></p>
<p style="top:340.4pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">differences</span></p>
<p style="top:324.4pt;left:467.7pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Vitamin C supplementation</span></p>
<p style="top:332.4pt;left:476.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">did not accelerate fracture</span></p>
<p style="top:340.4pt;left:476.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">healing process</span></p>
<p style="top:372.2pt;left:35.9pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Duygulu</span></p>
<p style="top:380.2pt;left:44.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">et al</span><sup><span style="font-family:AdvPAEB8,serif;font-size:4.2pt">5</span></sup></p>
<p style="top:388.2pt;left:44.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">(2007)</span></p>
<p style="top:372.2pt;left:69.1pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">None; N/A</span></p>
<p style="top:372.2pt;left:129.0pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Intraperitoneally 500 mg/kg</span></p>
<p style="top:380.2pt;left:189.5pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">vitamin C</span></p>
<p style="top:388.2pt;left:189.5pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">(</span><span style="font-family:AdvP4C4E74,serif;font-size:6.0pt">&#xfe;</span><span style="font-family:AdvPAEB8,serif;font-size:6.0pt"> 100 mg/kg</span></p>
<p style="top:396.2pt;left:189.5pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">zymosan per</span></p>
<p style="top:404.1pt;left:189.5pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">day for first</span></p>
<p style="top:412.1pt;left:189.5pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">5 days)</span></p>
<p style="top:372.2pt;left:230.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Once per day</span></p>
<p style="top:372.2pt;left:277.3pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">21 days</span></p>
<p style="top:372.2pt;left:327.2pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Caged laboratory</span></p>
<p style="top:380.2pt;left:336.1pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">conditions</span></p>
<p style="top:388.2pt;left:336.1pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">with standard</span></p>
<p style="top:396.2pt;left:336.1pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">diet and water</span></p>
<p style="top:372.2pt;left:380.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Oxidative stress impaired</span></p>
<p style="top:380.2pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">bone healing;</span></p>
<p style="top:388.2pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">histopathological,</span></p>
<p style="top:396.2pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">radiographic (bony union),</span></p>
<p style="top:404.1pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">and electromyographic</span></p>
<p style="top:412.1pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">(collagen fibrils)</span></p>
<p style="top:420.1pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">evaluations for vitamin C</span></p>
<p style="top:428.0pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">group were similar to that</span></p>
<p style="top:436.0pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">of control group; and</span></p>
<p style="top:443.9pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">significant difference in</span></p>
<p style="top:451.9pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">zymosan-only group for</span></p>
<p style="top:459.9pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">improved fracture healing</span></p>
<p style="top:372.2pt;left:467.7pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Free oxygen radicals have</span></p>
<p style="top:380.2pt;left:476.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">role in disruption of</span></p>
<p style="top:388.2pt;left:476.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">fracture healing, and</span></p>
<p style="top:396.2pt;left:476.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">vitamin C can partially</span></p>
<p style="top:404.1pt;left:476.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">prevent negative effects</span></p>
<p style="top:467.9pt;left:35.9pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Yilmaz</span></p>
<p style="top:475.9pt;left:44.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">et al</span><sup><span style="font-family:AdvPAEB8,serif;font-size:4.2pt">41</span></sup></p>
<p style="top:483.8pt;left:44.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">(2001)</span></p>
<p style="top:467.9pt;left:69.1pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">None;</span></p>
<p style="top:475.9pt;left:78.0pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">weightbearing</span></p>
<p style="top:467.9pt;left:129.0pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Intramuscularly</span></p>
<p style="top:467.9pt;left:180.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">0.5 mg/kg</span></p>
<p style="top:475.9pt;left:189.5pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">vitamin C</span></p>
<p style="top:467.9pt;left:230.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Once</span></p>
<p style="top:467.9pt;left:277.3pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">5 days, 10 days,</span></p>
<p style="top:475.9pt;left:286.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">15 days, and</span></p>
<p style="top:483.8pt;left:286.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">20 days</span></p>
<p style="top:467.9pt;left:327.2pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Caged with rat</span></p>
<p style="top:475.9pt;left:336.1pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">food,</span></p>
<p style="top:483.8pt;left:336.1pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">unlimited</span></p>
<p style="top:491.8pt;left:336.1pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">access to</span></p>
<p style="top:499.8pt;left:336.1pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">water, and</span></p>
<p style="top:507.7pt;left:336.1pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">unrestricted</span></p>
<p style="top:515.7pt;left:336.1pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">activity</span></p>
<p style="top:467.9pt;left:380.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">No significant difference</span></p>
<p style="top:475.9pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">between groups overall;</span></p>
<p style="top:483.8pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">and vitamin C group was</span></p>
<p style="top:491.8pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">faster in chondroid cell</span></p>
<p style="top:499.8pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">development, chondrocyte</span></p>
<p style="top:507.7pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">hypertrophy, and</span></p>
<p style="top:515.7pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">fibrocartilaginous callus</span></p>
<p style="top:523.7pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">development than control</span></p>
<p style="top:531.6pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">group (</span><span style="font-family:AdvPAEB9,serif;font-size:6.0pt">P</span><span style="font-family:AdvTTab7e17fd,serif;font-size:6.0pt"> &gt;</span><span style="font-family:AdvPAEB8,serif;font-size:6.0pt"> .05)</span></p>
<p style="top:467.9pt;left:467.7pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Although there was no</span></p>
<p style="top:475.9pt;left:476.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">difference in quality of</span></p>
<p style="top:483.8pt;left:476.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">fracture healing, vitamin</span></p>
<p style="top:491.8pt;left:476.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">C&#x2013;supplemented group</span></p>
<p style="top:499.8pt;left:476.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">was faster in healing</span></p>
<p style="top:507.7pt;left:476.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">process compared with</span></p>
<p style="top:515.7pt;left:476.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">controls</span></p>
<p style="top:539.6pt;left:35.9pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Fu et al</span><sup><span style="font-family:AdvPAEB8,serif;font-size:4.2pt">10</span></sup></p>
<p style="top:547.6pt;left:44.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">(2013)</span></p>
<p style="top:539.6pt;left:69.1pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">ACL reconstruction;</span></p>
<p style="top:547.6pt;left:78.0pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">weightbearing</span></p>
<p style="top:555.6pt;left:78.0pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">without</span></p>
<p style="top:563.5pt;left:78.0pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">immobilization</span></p>
<p style="top:539.6pt;left:129.0pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Intraoperative</span></p>
<p style="top:547.6pt;left:137.9pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">irrigation</span></p>
<p style="top:555.6pt;left:137.9pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">solution</span></p>
<p style="top:539.6pt;left:180.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">3 mg/mL,</span></p>
<p style="top:547.6pt;left:189.5pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">10 mg/mL,</span></p>
<p style="top:555.6pt;left:189.5pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">or 30 mg/mL</span></p>
<p style="top:563.5pt;left:189.5pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">(10 mL)</span></p>
<p style="top:571.5pt;left:189.5pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">vitamin C</span></p>
<p style="top:539.6pt;left:230.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Once</span></p>
<p style="top:539.6pt;left:277.3pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">1 day, 4 days,</span></p>
<p style="top:547.6pt;left:286.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">7 days, and</span></p>
<p style="top:555.6pt;left:286.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">6 weeks</span></p>
<p style="top:539.6pt;left:327.2pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Caged</span></p>
<p style="top:539.6pt;left:380.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Vitamin C group had</span></p>
<p style="top:547.6pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">significantly reduced</span></p>
<p style="top:555.6pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">serum C-reactive protein</span></p>
<p style="top:563.5pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">levels at day 1, 3 mg/mL of</span></p>
<p style="top:571.5pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">vitamin C led to better</span></p>
<p style="top:579.4pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">restoration of</span></p>
<p style="top:587.4pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">anteroposterior knee</span></p>
<p style="top:595.4pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">stability at 6 weeks</span></p>
<p style="top:603.4pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">compared with control</span></p>
<p style="top:611.4pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">group, 3 and 10 mg/mL of</span></p>
<p style="top:619.3pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">vitamin C significantly</span></p>
<p style="top:627.3pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">reduced graft deterioration</span></p>
<p style="top:635.3pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">at 6 weeks, and no</span></p>
<p style="top:643.2pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">significant difference</span></p>
<p style="top:651.2pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">between groups at 42</span></p>
<p style="top:659.1pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">weeks for graft</span></p>
<p style="top:667.1pt;left:389.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">incorporation</span></p>
<p style="top:539.6pt;left:467.7pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Low dose of vitamin C</span></p>
<p style="top:547.6pt;left:476.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">demonstrated short-term</span></p>
<p style="top:555.6pt;left:476.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">improvements after ACL</span></p>
<p style="top:563.5pt;left:476.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">reconstruction compared</span></p>
<p style="top:571.5pt;left:476.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">with controls, but there</span></p>
<p style="top:579.4pt;left:476.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">were no significant</span></p>
<p style="top:587.4pt;left:476.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">differences in ACL graft</span></p>
<p style="top:595.4pt;left:476.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">incorporation between</span></p>
<p style="top:603.4pt;left:476.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">groups</span></p>
<p style="top:682.3pt;left:47.8pt;line-height:5.6pt"><span style="font-family:AdvPAEB9,serif;font-size:5.6pt">a</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">The intervention was initiated on postinjury day 0 in all studies (n</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 7). ACL, anterior cruciate ligament; N/A, not available.</span></p>
<p style="top:35.2pt;left:35.9pt;line-height:8.5pt"><span style="font-family:AdvPAEB9,serif;font-size:8.5pt">The Orthopaedic Journal of Sports Medicine</span></p>
<p style="top:35.2pt;left:329.8pt;line-height:8.5pt"><span style="font-family:AdvPAEB9,serif;font-size:8.5pt">Efficacy of Vitamin C After Musculoskeletal Injuries</span></p>
<p style="top:35.2pt;left:544.3pt;line-height:8.5pt"><span style="font-family:AdvPAEBA,serif;font-size:8.5pt">5</span></p>


<p style="top:294.9pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">of orally supplemented vitamin C ranged from 60 mg twice</span></p>
<p style="top:305.9pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">daily to 500 mg twice daily for a minimum of 7 days and</span></p>
<p style="top:316.9pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">maximum of 3 months. The 2 studies evaluating bone frac-</span></p>
<p style="top:327.8pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">ture healing began vitamin C supplementation on day 1</span></p>
<p style="top:338.8pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">after the fracture.</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">6,32</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">The study evaluating oxidative stress</span></p>
<p style="top:349.8pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">and muscle recovery began vitamin C supplementation 2</span></p>
<p style="top:360.7pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">weeks before the planned ACLR.</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">2</span></sup></p>
<p style="top:371.6pt;left:47.8pt;line-height:9.0pt"><span style="font-family:AdvPAEB9,serif;font-size:9.0pt">Clinical Outcomes.</span><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> The clinical trial evaluating muscle</span></p>
<p style="top:382.6pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">recovery after ACLR reported no significant differences</span></p>
<p style="top:393.6pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">between the vitamin C and control groups.</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">2</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">However, base-</span></p>
<p style="top:404.5pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">line vitamin C status was associated with significant</span></p>
<p style="top:415.5pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">improvements in strength, suggesting that long-term die-</span></p>
<p style="top:426.5pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">tary habits may be more effective than short-term supple-</span></p>
<p style="top:437.4pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">ments.</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">2</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">The results of the 2 clinical trials evaluating bone</span></p>
<p style="top:448.4pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">healing after fractures were conflicting. Sandukji et al</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">32</span></sup></p>
<p style="top:459.4pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">reported significant increases in osteocalcin levels and the</span></p>
<p style="top:470.3pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">activity of alkaline phosphatase in the blood plasma of</span></p>
<p style="top:481.2pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">patients who received antioxidants for 2 weeks (</span><span style="font-family:AdvPAEB9,serif;font-size:9.0pt">P</span><span style="font-family:AdvTTab7e17fd,serif;font-size:9.0pt"> &lt;</span><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> .05),</span></p>
<p style="top:492.2pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">both of which are bone markers previously reported to be</span></p>
<p style="top:503.2pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">positively correlated with bone mineral density (BMD).</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">13,35</span></sup></p>
<p style="top:514.1pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">However, these authors did not report on the long-term</span></p>
<p style="top:525.1pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">results of fracture healing. In contrast, Ekrol et al</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">6</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">noted</span></p>
<p style="top:536.1pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">no significant difference in the time to fracture healing in</span></p>
<p style="top:547.0pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">patients with long bone fractures who were supplemented</span></p>
<p style="top:557.9pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">with vitamin C compared with controls. Furthermore, there</span></p>
<p style="top:568.9pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">were no significant differences between the 2 treatment</span></p>
<p style="top:579.9pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">groups at 1-year follow-up.</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">6</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">No adverse effects were reported</span></p>
<p style="top:590.8pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">in any clinical study (n</span><span style="font-family:AdvP4C4E74,serif;font-size:9.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> 3) regarding the use of vitamin C,</span></p>
<p style="top:601.8pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">and 1 study reported a dropout rate of 26</span><span style="font-family:AdvP4C4E59,serif;font-size:9.0pt">%</span><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> and a compliance</span></p>
<p style="top:612.8pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">rate of 84</span><span style="font-family:AdvP4C4E59,serif;font-size:9.0pt">%</span><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">.</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">6</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">Despite this high dropout rate, the authors still</span></p>
<p style="top:623.7pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">managed to include a large sample size (n</span><span style="font-family:AdvP4C4E74,serif;font-size:9.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> 162) in their</span></p>
<p style="top:634.7pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">final analysis.</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">6</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">Further results are detailed in Table 4.</span></p>
<p style="top:664.2pt;left:35.9pt;line-height:10.0pt"><span style="font-family:AdvPA183,serif;font-size:10.0pt">DISCUSSION</span></p>
<p style="top:684.9pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">The most important finding of this systematic review was</span></p>
<p style="top:695.9pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">that there is preclinical evidence that vitamin C supple-</span></p>
<p style="top:706.9pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">mentation accelerates bone healing after fractures,</span></p>
<p style="top:717.8pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">increases type I collagen synthesis, and reduces oxidative</span></p>
<p style="top:294.9pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">stress parameters (detailed in Figure 2). However, clinical</span></p>
<p style="top:306.1pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">evidence does not replicate the results seen in animal mod-</span></p>
<p style="top:317.2pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">els to date. Furthermore, high doses (ie,</span><span style="font-family:AdvP4C4E74,serif;font-size:9.0pt"> &#xfffd;</span><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">1000 mg/d) of</span></p>
<p style="top:328.3pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">orally administered vitamin C had no direct benefit com-</span></p>
<p style="top:339.5pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">pared with controls. Conversely, low doses (ie, 60 mg/d) of</span></p>
<p style="top:350.6pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">orally administered vitamin C had a significant difference</span></p>
<p style="top:361.8pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">of increased bone biomarkers compared with controls.</span></p>
<p style="top:372.9pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">Overall, there are limited data regarding the efficacy of</span></p>
<p style="top:384.1pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">vitamin C supplementation after musculoskeletal injuries.</span></p>
<p style="top:395.2pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">No adverse effects were reported with vitamin C supple-</span></p>
<p style="top:406.3pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">mentation in either animal models or human participants.</span></p>
<p style="top:417.3pt;left:316.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">After a musculoskeletal injury, the activation of inflam-</span></p>
<p style="top:428.4pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">matory cells has been observed to overproduce ROS, caus-</span></p>
<p style="top:439.6pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">ing deleterious oxidative stress. Oxidative stress has been</span></p>
<p style="top:450.7pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">described as an imbalance between ROS and antioxi-</span></p>
<p style="top:461.8pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">dants,</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">19</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">resulting in a hostile healing environment that</span></p>
<p style="top:473.0pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">negatively affects the viability and proliferation of</span></p>
<p style="top:484.1pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">recruited collagen-producing cells and ultimately promot-</span></p>
<p style="top:495.2pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">ing apoptosis.</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">14,16,17,21</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">Vitamin C as an antioxidant is capa-</span></p>
<p style="top:506.4pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">ble of neutralizing ROS through redox reactions, relieving</span></p>
<p style="top:517.5pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">oxidative stress due to inflammation. All 3 preclinical stud-</span></p>
<p style="top:528.6pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">ies evaluating oxidative stress reported that vitamin C was</span></p>
<p style="top:539.8pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">effective in reducing oxidative stress after injuries by</span></p>
<p style="top:550.9pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">decreasing endogenous or exogenous ROS, signified by an</span></p>
<p style="top:562.1pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">improved tissue composition in ligaments, tendons, and</span></p>
<p style="top:573.2pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">bone.</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">5,10,19</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">However, only 1 of the 3 studies reported vita-</span></p>
<p style="top:584.4pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">min C as an antagonist for oxidative stress after 2 weeks,</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">19</span></sup></p>
<p style="top:595.5pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">limiting preclinical support for the clinical implications as a</span></p>
<p style="top:606.6pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">postinjury supplement.</span></p>
<p style="top:617.6pt;left:316.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">Four of 5 studies investigating the effects of vitamin C on</span></p>
<p style="top:628.7pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">collagen production suggested that vitamin C was effective</span></p>
<p style="top:639.9pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">by stimulating biochemical pathways associated with colla-</span></p>
<p style="top:651.0pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">gen synthesis. Omeroglu et al</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">25</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">reported that vitamin C</span></p>
<p style="top:662.1pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">increased the activity for procollagen-secreting fibroblasts</span></p>
<p style="top:673.3pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">and overall type I collagen production. The stimulation of</span></p>
<p style="top:684.4pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">collagen-producing cells was also reported by Yilmaz</span></p>
<p style="top:695.5pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">et al,</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">41</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">who observed accelerated rates of chondrocyte</span></p>
<p style="top:706.6pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">development and hypertrophy. Sandukji et al</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">32</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">reported</span></p>
<p style="top:717.8pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">elevations in alkaline phosphatase, a vitamin C&#x2013;dependent</span></p>
<p style="top:71.5pt;left:273.0pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">TABLE 3</span></p>
<p style="top:82.5pt;left:143.1pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">Clinical Studies: Demographics, Study Design, and Experimental Focus</span></p>
<p style="top:121.3pt;left:35.9pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Study</span></p>
<p style="top:101.3pt;left:98.1pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Study Design</span></p>
<p style="top:111.3pt;left:107.1pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(Level of</span></p>
<p style="top:121.3pt;left:104.9pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Evidence)</span></p>
<p style="top:121.3pt;left:181.4pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Participants</span></p>
<p style="top:121.3pt;left:278.9pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Abnormality</span></p>
<p style="top:121.3pt;left:376.3pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Experimental Groups</span></p>
<p style="top:111.3pt;left:490.6pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Experimental</span></p>
<p style="top:121.3pt;left:505.1pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Focus</span></p>
<p style="top:139.5pt;left:35.9pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Barker et al</span><sup><span style="font-family:AdvPAEB8,serif;font-size:5.6pt">2</span></sup></p>
<p style="top:149.5pt;left:44.8pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(2009)</span></p>
<p style="top:139.5pt;left:92.2pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Randomized</span></p>
<p style="top:149.5pt;left:101.2pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">controlled</span></p>
<p style="top:159.5pt;left:101.2pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">trial (level 1)</span></p>
<p style="top:139.5pt;left:159.8pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Male with preoperative/</span></p>
<p style="top:149.5pt;left:168.8pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">postoperative</span></p>
<p style="top:159.5pt;left:168.8pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">supplementation</span></p>
<p style="top:169.4pt;left:168.8pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(N</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 20)</span></p>
<p style="top:139.5pt;left:254.4pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Anterior cruciate</span></p>
<p style="top:149.5pt;left:263.4pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">ligament tear</span></p>
<p style="top:139.5pt;left:355.9pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(1) Vitamins C and E (n</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 10)</span></p>
<p style="top:149.5pt;left:364.8pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">and (2) placebo (n</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 10)</span></p>
<p style="top:139.5pt;left:482.6pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Muscle atrophy/</span></p>
<p style="top:149.5pt;left:491.5pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">recovery and</span></p>
<p style="top:159.5pt;left:491.5pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">oxidative stress</span></p>
<p style="top:169.4pt;left:491.5pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">parameters</span></p>
<p style="top:179.4pt;left:35.9pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Ekrol et al</span><sup><span style="font-family:AdvPAEB8,serif;font-size:5.6pt">6</span></sup></p>
<p style="top:189.3pt;left:35.9pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(2014)</span></p>
<p style="top:179.4pt;left:92.2pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Controlled trial</span></p>
<p style="top:189.3pt;left:101.2pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(level 2)</span></p>
<p style="top:179.4pt;left:159.8pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Male and female with</span></p>
<p style="top:189.3pt;left:168.8pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">postinjury</span></p>
<p style="top:199.3pt;left:168.8pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">supplementation</span></p>
<p style="top:209.2pt;left:168.8pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(N</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 336)</span></p>
<p style="top:179.4pt;left:254.4pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Distal radius fracture</span></p>
<p style="top:179.4pt;left:355.9pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Displaced fractures: (1) Vitamin</span></p>
<p style="top:189.3pt;left:364.8pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">C (n</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 94) and (2) placebo</span></p>
<p style="top:199.3pt;left:364.8pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(n</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 92)</span></p>
<p style="top:209.2pt;left:355.9pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Nondisplaced fractures: (1)</span></p>
<p style="top:219.2pt;left:365.8pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Vitamin C (n</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 75) and (2)</span></p>
<p style="top:229.2pt;left:365.8pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">placebo (n</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 75)</span></p>
<p style="top:179.4pt;left:482.6pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Bone healing</span></p>
<p style="top:239.2pt;left:35.9pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Sandukji</span></p>
<p style="top:249.1pt;left:44.8pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">et al</span><sup><span style="font-family:AdvPAEB8,serif;font-size:5.6pt">32</span></sup></p>
<p style="top:259.1pt;left:44.8pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(2011)</span></p>
<p style="top:239.2pt;left:92.2pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Randomized</span></p>
<p style="top:249.1pt;left:101.2pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">controlled</span></p>
<p style="top:259.1pt;left:101.2pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">trial (level 1)</span></p>
<p style="top:239.2pt;left:159.8pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Male with postoperative</span></p>
<p style="top:249.1pt;left:168.8pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">supplementation</span></p>
<p style="top:259.1pt;left:168.8pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(N</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 55)</span></p>
<p style="top:239.2pt;left:254.4pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Long bone fracture</span></p>
<p style="top:249.1pt;left:263.4pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(humerus, radius,</span></p>
<p style="top:259.1pt;left:263.4pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">ulna, tibia, femur)</span></p>
<p style="top:239.2pt;left:355.9pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">(1) Vitamins A, C, and E and</span></p>
<p style="top:249.1pt;left:364.8pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">selenium (n</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 20) and (2)</span></p>
<p style="top:259.1pt;left:364.8pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">control (n</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> 35)</span></p>
<p style="top:239.2pt;left:482.6pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Bone healing and</span></p>
<p style="top:249.1pt;left:491.5pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">oxidative stress</span></p>
<p style="top:259.1pt;left:491.5pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">parameters</span></p>
<p style="top:35.2pt;left:35.9pt;line-height:8.5pt"><span style="font-family:AdvPAEBA,serif;font-size:8.5pt">6</span></p>
<p style="top:35.2pt;left:50.7pt;line-height:8.5pt"><span style="font-family:AdvPAEB9,serif;font-size:8.5pt">DePhillipo et al</span></p>
<p style="top:35.2pt;left:374.3pt;line-height:8.5pt"><span style="font-family:AdvPAEB9,serif;font-size:8.5pt">The Orthopaedic Journal of Sports Medicine</span></p>


<p style="top:498.2pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">enzyme involved in osteoblastic differentiation and bone</span></p>
<p style="top:509.2pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">formation.</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">8,11,18,26</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">Sarisozen et al</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">33</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">also suggested that the</span></p>
<p style="top:520.2pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">observed increase in callus formation due to vitamin C</span></p>
<p style="top:531.1pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">resulted from osteoblast proliferation, although cellular</span></p>
<p style="top:542.1pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">activity was not quantified. Overall, these studies provide</span></p>
<p style="top:553.1pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">evidence that vitamin C may be effective in promoting col-</span></p>
<p style="top:564.1pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">lagen synthesis in vivo, although further clinical studies</span></p>
<p style="top:575.1pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">are needed to strengthen the implications for postoperative</span></p>
<p style="top:586.1pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">vitamin C supplementation.</span></p>
<p style="top:597.0pt;left:316.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">Barker et al</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">2</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">reported that vitamin C and E supplemen-</span></p>
<p style="top:608.0pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">tation was ineffective in potentiating the improvement in</span></p>
<p style="top:619.0pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">force production of the injured limb after ACLR. However,</span></p>
<p style="top:629.9pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">baseline vitamin C status was associated with beneficial</span></p>
<p style="top:640.9pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">outcomes in strength, suggesting that long-term dietary</span></p>
<p style="top:651.9pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">habits may be more effective than short-term supplements.</span></p>
<p style="top:662.9pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">Ligamentous integrity at follow-up (3 months postopera-</span></p>
<p style="top:673.9pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">tively) was not examined</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">2</span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">; thus, collagen synthesis and lig-</span></p>
<p style="top:684.9pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">ament healing with vitamin C supplementation have not</span></p>
<p style="top:695.9pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">been investigated clinically in the current literature.</span></p>
<p style="top:706.8pt;left:316.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">Ekrol et al</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">6</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">found no significant difference in functional</span></p>
<p style="top:717.8pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">outcomes at 1 year between patients treated with vitamin C</span></p>
<p style="top:71.5pt;left:273.0pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">TABLE 4</span></p>
<p style="top:82.5pt;left:147.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">Clinical Studies: Treatment Protocols After Musculoskeletal Injuries</span><sup><span style="font-family:AdvPAEB9,serif;font-size:6.3pt">a</span></sup></p>
<p style="top:108.9pt;left:35.9pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Study</span></p>
<p style="top:101.0pt;left:75.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Treatment and</span></p>
<p style="top:108.9pt;left:79.9pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Restrictions</span></p>
<p style="top:101.0pt;left:135.5pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Start of</span></p>
<p style="top:108.9pt;left:131.7pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Vitamin C</span></p>
<p style="top:101.0pt;left:176.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Route of</span></p>
<p style="top:108.9pt;left:175.3pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Exposure</span></p>
<p style="top:108.9pt;left:231.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Dosage</span></p>
<p style="top:108.9pt;left:270.7pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Frequency</span></p>
<p style="top:108.9pt;left:312.2pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Duration</span></p>
<p style="top:108.9pt;left:361.2pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Conditions</span></p>
<p style="top:108.9pt;left:430.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Results</span></p>
<p style="top:108.9pt;left:498.7pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Conclusion</span></p>
<p style="top:125.2pt;left:35.9pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Barker</span></p>
<p style="top:133.2pt;left:44.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">et al</span><sup><span style="font-family:AdvPAEB8,serif;font-size:4.2pt">2</span></sup></p>
<p style="top:141.1pt;left:44.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">(2009)</span></p>
<p style="top:125.2pt;left:65.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">ACLR with double-</span></p>
<p style="top:133.2pt;left:74.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">bundle hamstring</span></p>
<p style="top:141.1pt;left:74.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">autograft (n</span><span style="font-family:AdvP4C4E74,serif;font-size:6.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:6.0pt"> 19</span></p>
<p style="top:149.1pt;left:74.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">[95</span><span style="font-family:AdvP4C4E59,serif;font-size:6.0pt">%</span><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">]) and bone&#x2013;</span></p>
<p style="top:157.0pt;left:74.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">patellar tendon&#x2013;</span></p>
<p style="top:165.0pt;left:74.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">bone autograft</span></p>
<p style="top:173.0pt;left:74.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">(n</span><span style="font-family:AdvP4C4E74,serif;font-size:6.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:6.0pt"> 1 [5</span><span style="font-family:AdvP4C4E59,serif;font-size:6.0pt">%</span><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">]);</span></p>
<p style="top:180.9pt;left:74.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">nonweightbearing</span></p>
<p style="top:188.9pt;left:74.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">for 5 days (n</span><span style="font-family:AdvP4C4E74,serif;font-size:6.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:6.0pt"> 20</span></p>
<p style="top:196.9pt;left:74.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">[100</span><span style="font-family:AdvP4C4E59,serif;font-size:6.0pt">%</span><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">])</span></p>
<p style="top:125.2pt;left:130.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">2 weeks</span></p>
<p style="top:133.2pt;left:139.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">before</span></p>
<p style="top:141.1pt;left:139.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">ACLR</span></p>
<p style="top:125.2pt;left:179.5pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Orally</span></p>
<p style="top:125.2pt;left:214.9pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">500 mg vitamin C</span></p>
<p style="top:133.2pt;left:223.9pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">and 200 IU</span></p>
<p style="top:141.1pt;left:223.9pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">vitamin E</span></p>
<p style="top:125.2pt;left:270.7pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Twice</span></p>
<p style="top:133.2pt;left:279.7pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">daily</span></p>
<p style="top:125.2pt;left:302.9pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">3 months</span></p>
<p style="top:125.2pt;left:349.7pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Diet not restricted,</span></p>
<p style="top:133.2pt;left:358.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">and restricted</span></p>
<p style="top:141.1pt;left:358.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">NSAID use for</span></p>
<p style="top:149.1pt;left:358.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">duration of</span></p>
<p style="top:157.0pt;left:358.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">study</span></p>
<p style="top:125.2pt;left:405.5pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Significant increase in</span></p>
<p style="top:133.2pt;left:414.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">peak isometric force of</span></p>
<p style="top:141.1pt;left:414.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">injured limb in both</span></p>
<p style="top:149.1pt;left:414.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">groups (</span><span style="font-family:AdvPAEB9,serif;font-size:6.0pt">P</span><span style="font-family:AdvTTab7e17fd,serif;font-size:6.0pt"> &lt;</span><span style="font-family:AdvPAEB8,serif;font-size:6.0pt"> .05),</span></p>
<p style="top:157.0pt;left:414.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">vitamin C/E did not</span></p>
<p style="top:165.0pt;left:414.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">augment strength</span></p>
<p style="top:173.0pt;left:414.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">gains (</span><span style="font-family:AdvPAEB9,serif;font-size:6.0pt">P</span><span style="font-family:AdvTTab7e17fd,serif;font-size:6.0pt"> &gt;</span><span style="font-family:AdvPAEB8,serif;font-size:6.0pt"> .05), and</span></p>
<p style="top:180.9pt;left:414.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">significant correlation</span></p>
<p style="top:188.9pt;left:414.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">between baseline</span></p>
<p style="top:196.9pt;left:414.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">vitamin C and</span></p>
<p style="top:204.9pt;left:414.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">strength recovery</span></p>
<p style="top:212.8pt;left:414.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">after ACLR (</span><span style="font-family:AdvPAEB9,serif;font-size:6.0pt">P</span><span style="font-family:AdvTTab7e17fd,serif;font-size:6.0pt"> &lt;</span><span style="font-family:AdvPAEB8,serif;font-size:6.0pt"> .05)</span></p>
<p style="top:125.2pt;left:478.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Vitamin E and C</span></p>
<p style="top:133.2pt;left:487.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">supplementation was</span></p>
<p style="top:141.1pt;left:487.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">ineffective in</span></p>
<p style="top:149.1pt;left:487.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">augmenting</span></p>
<p style="top:157.0pt;left:487.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">improvement in force</span></p>
<p style="top:165.0pt;left:487.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">production by injured</span></p>
<p style="top:173.0pt;left:487.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">limb; however,</span></p>
<p style="top:180.9pt;left:487.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">baseline vitamin C</span></p>
<p style="top:188.9pt;left:487.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">status was associated</span></p>
<p style="top:196.9pt;left:487.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">with beneficial</span></p>
<p style="top:204.9pt;left:487.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">outcomes in strength,</span></p>
<p style="top:212.8pt;left:487.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">suggesting that long-</span></p>
<p style="top:220.8pt;left:487.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">term dietary habits</span></p>
<p style="top:228.8pt;left:487.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">are more effective</span></p>
<p style="top:236.7pt;left:487.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">than short-term</span></p>
<p style="top:244.7pt;left:487.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">supplements</span></p>
<p style="top:252.7pt;left:35.9pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Ekrol</span></p>
<p style="top:260.7pt;left:44.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">et al</span><sup><span style="font-family:AdvPAEB8,serif;font-size:4.2pt">6</span></sup></p>
<p style="top:268.6pt;left:44.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">(2014)</span></p>
<p style="top:252.7pt;left:65.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Surgical (displaced</span></p>
<p style="top:260.7pt;left:74.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">fracture): open</span></p>
<p style="top:268.6pt;left:74.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">reduction internal/</span></p>
<p style="top:276.6pt;left:74.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">external fixation</span></p>
<p style="top:284.6pt;left:74.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">(n</span><span style="font-family:AdvP4C4E74,serif;font-size:6.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:6.0pt"> 186 [55</span><span style="font-family:AdvP4C4E59,serif;font-size:6.0pt">%</span><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">])</span></p>
<p style="top:292.5pt;left:65.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Conservative</span></p>
<p style="top:300.5pt;left:75.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">(nondisplaced</span></p>
<p style="top:308.5pt;left:75.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">fracture): cast</span></p>
<p style="top:316.4pt;left:75.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">(n</span><span style="font-family:AdvP4C4E74,serif;font-size:6.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:6.0pt"> 150 [45</span><span style="font-family:AdvP4C4E59,serif;font-size:6.0pt">%</span><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">])</span></p>
<p style="top:252.7pt;left:130.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Day 1 after</span></p>
<p style="top:260.7pt;left:139.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">fracture</span></p>
<p style="top:252.7pt;left:179.5pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Orally</span></p>
<p style="top:252.7pt;left:214.9pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">500 mg vitamin C</span></p>
<p style="top:252.7pt;left:270.7pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Daily</span></p>
<p style="top:252.7pt;left:302.9pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">50 days</span></p>
<p style="top:252.7pt;left:349.7pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Diet not restricted</span></p>
<p style="top:260.7pt;left:358.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">but monitored,</span></p>
<p style="top:268.6pt;left:358.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">and excluded</span></p>
<p style="top:276.6pt;left:358.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">patients</span></p>
<p style="top:284.6pt;left:358.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">currently</span></p>
<p style="top:292.5pt;left:358.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">taking vitamin</span></p>
<p style="top:300.5pt;left:358.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">C before</span></p>
<p style="top:308.5pt;left:358.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">fracture</span></p>
<p style="top:252.7pt;left:405.5pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Time to fracture healing</span></p>
<p style="top:260.7pt;left:414.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">did not differ between</span></p>
<p style="top:268.6pt;left:414.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">treatment groups</span></p>
<p style="top:276.6pt;left:414.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">(</span><span style="font-family:AdvPAEB9,serif;font-size:6.0pt">P</span><span style="font-family:AdvP4C4E74,serif;font-size:6.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:6.0pt"> .42 and .23), and</span></p>
<p style="top:284.6pt;left:414.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">no difference in</span></p>
<p style="top:292.5pt;left:414.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">functional outcomes</span></p>
<p style="top:300.5pt;left:414.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">at 1 year (</span><span style="font-family:AdvPAEB9,serif;font-size:6.0pt">P</span><span style="font-family:AdvTTab7e17fd,serif;font-size:6.0pt"> &gt;</span><span style="font-family:AdvPAEB8,serif;font-size:6.0pt"> .05)</span></p>
<p style="top:252.7pt;left:478.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">No difference in DASH</span></p>
<p style="top:260.7pt;left:487.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">score, other functional</span></p>
<p style="top:268.6pt;left:487.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">outcomes, occurrence</span></p>
<p style="top:276.6pt;left:487.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">of CRPS, or fracture</span></p>
<p style="top:284.6pt;left:487.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">healing with vitamin</span></p>
<p style="top:292.5pt;left:487.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">C treatment in</span></p>
<p style="top:300.5pt;left:487.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">patients with distal</span></p>
<p style="top:308.5pt;left:487.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">radius fracture</span></p>
<p style="top:324.4pt;left:35.9pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Sandukji</span></p>
<p style="top:332.4pt;left:44.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">et al</span><sup><span style="font-family:AdvPAEB8,serif;font-size:4.2pt">32</span></sup></p>
<p style="top:340.4pt;left:44.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">(2011)</span></p>
<p style="top:324.4pt;left:65.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Surgery: open</span></p>
<p style="top:332.4pt;left:74.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">reduction internal</span></p>
<p style="top:340.4pt;left:74.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">fixation (n</span><span style="font-family:AdvP4C4E74,serif;font-size:6.0pt"> &#xbc;</span><span style="font-family:AdvPAEB8,serif;font-size:6.0pt"> 55</span></p>
<p style="top:348.3pt;left:74.6pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">[100</span><span style="font-family:AdvP4C4E59,serif;font-size:6.0pt">%</span><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">])</span></p>
<p style="top:324.4pt;left:130.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Day 1 after</span></p>
<p style="top:332.4pt;left:139.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">fracture</span></p>
<p style="top:324.4pt;left:173.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Orally and</span></p>
<p style="top:332.4pt;left:173.7pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">intravenously</span></p>
<p style="top:324.4pt;left:214.9pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Groups 1/2: 300 mg</span></p>
<p style="top:332.4pt;left:223.9pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">vitamin A, 10</span></p>
<p style="top:340.4pt;left:223.9pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">mg vitamin E,</span></p>
<p style="top:348.3pt;left:223.9pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">60 mg vitamin</span></p>
<p style="top:356.3pt;left:223.9pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">C, and</span></p>
<p style="top:364.3pt;left:223.9pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">75 mg selenium</span></p>
<p style="top:372.2pt;left:214.9pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Groups 3/4:</span></p>
<p style="top:380.2pt;left:224.9pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">1000 mg/d</span></p>
<p style="top:388.2pt;left:224.9pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">cephalosporin</span></p>
<p style="top:396.2pt;left:224.9pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">for 3 days, 50</span></p>
<p style="top:404.1pt;left:224.9pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">mg oral</span></p>
<p style="top:412.1pt;left:224.9pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">diclofenac, and</span></p>
<p style="top:420.1pt;left:224.9pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">500 mg</span></p>
<p style="top:428.0pt;left:224.9pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">paracetamol</span></p>
<p style="top:436.0pt;left:224.9pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">twice daily for</span></p>
<p style="top:443.9pt;left:224.9pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">15 days</span></p>
<p style="top:324.4pt;left:270.7pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Twice</span></p>
<p style="top:332.4pt;left:279.7pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">daily</span></p>
<p style="top:324.4pt;left:302.9pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Group 1: 7 days</span></p>
<p style="top:332.4pt;left:302.9pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Group 2: 15</span></p>
<p style="top:340.4pt;left:312.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">days</span></p>
<p style="top:348.3pt;left:302.9pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Groups 3/4: 15</span></p>
<p style="top:356.3pt;left:312.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">days</span></p>
<p style="top:324.4pt;left:370.7pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">N/R</span></p>
<p style="top:324.4pt;left:405.5pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Osteocalcin level and</span></p>
<p style="top:332.4pt;left:414.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">activity of alkaline</span></p>
<p style="top:340.4pt;left:414.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">phosphatase were</span></p>
<p style="top:348.3pt;left:414.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">markedly increased</span></p>
<p style="top:356.3pt;left:414.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">in plasma of patients</span></p>
<p style="top:364.3pt;left:414.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">who received</span></p>
<p style="top:372.2pt;left:414.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">antioxidants for 2</span></p>
<p style="top:380.2pt;left:414.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">weeks (</span><span style="font-family:AdvPAEB9,serif;font-size:6.0pt">P</span><span style="font-family:AdvTTab7e17fd,serif;font-size:6.0pt"> &lt;</span><span style="font-family:AdvPAEB8,serif;font-size:6.0pt"> .05), and</span></p>
<p style="top:388.2pt;left:414.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">level of plasma</span></p>
<p style="top:396.2pt;left:414.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">glutathione was</span></p>
<p style="top:404.1pt;left:414.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">significantly</span></p>
<p style="top:412.1pt;left:414.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">increased only after 2</span></p>
<p style="top:420.1pt;left:414.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">weeks in patients who</span></p>
<p style="top:428.0pt;left:414.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">received antioxidants</span></p>
<p style="top:436.0pt;left:414.4pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">(</span><span style="font-family:AdvPAEB9,serif;font-size:6.0pt">P</span><span style="font-family:AdvTTab7e17fd,serif;font-size:6.0pt"> &lt;</span><span style="font-family:AdvPAEB8,serif;font-size:6.0pt"> .05)</span></p>
<p style="top:324.4pt;left:478.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">Elevation of osteocalcin</span></p>
<p style="top:332.4pt;left:487.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">levels might increase</span></p>
<p style="top:340.4pt;left:487.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">BMD and thus could</span></p>
<p style="top:348.3pt;left:487.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">accelerate healing of</span></p>
<p style="top:356.3pt;left:487.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">bone fractures</span></p>
<p style="top:364.3pt;left:487.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">because high levels of</span></p>
<p style="top:372.2pt;left:487.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">osteocalcin and</span></p>
<p style="top:380.2pt;left:487.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">alkaline phosphatase</span></p>
<p style="top:388.2pt;left:487.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">are positively</span></p>
<p style="top:396.2pt;left:487.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">correlated with BMD;</span></p>
<p style="top:404.1pt;left:487.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">and antioxidant</span></p>
<p style="top:412.1pt;left:487.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">vitamins A, C, and E</span></p>
<p style="top:420.1pt;left:487.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">and selenium could</span></p>
<p style="top:428.0pt;left:487.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">accelerate bone</span></p>
<p style="top:436.0pt;left:487.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">healing after long-</span></p>
<p style="top:443.9pt;left:487.8pt;line-height:6.0pt"><span style="font-family:AdvPAEB8,serif;font-size:6.0pt">bone fixation surgery</span></p>
<p style="top:459.1pt;left:47.8pt;line-height:5.6pt"><span style="font-family:AdvPAEB9,serif;font-size:5.6pt">a</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">Statistical significance was indicated at</span><span style="font-family:AdvPAEB9,serif;font-size:8.0pt"> P</span><span style="font-family:AdvTTab7e17fd,serif;font-size:8.0pt"> &lt;</span><span style="font-family:AdvPAEB8,serif;font-size:8.0pt"> .05. ACLR, anterior cruciate ligament reconstruction; BMD, bone mineral density; CRPS, chronic</span></p>
<p style="top:470.8pt;left:35.9pt;line-height:8.0pt"><span style="font-family:AdvPAEB8,serif;font-size:8.0pt">regional pain syndrome; DASH, Disabilities of the Arm, Shoulder and Hand; N/R, not reported; NSAID, nonsteroidal anti-inflammatory drug.</span></p>
<img style="position:absolute;transform:matrix(.5484377,0,-0,.5475354,-85.08731,571.13278)" src="data:image/jpeg;base64,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=">
<p style="top:684.9pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPA189,serif;font-size:9.0pt">Figure 2.</span><span style="font-family:AdvPA183,serif;font-size:9.0pt"> Reported effects of vitamin C supplementation after</span></p>
<p style="top:695.9pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPA183,serif;font-size:9.0pt">musculoskeletal injuries according to preclinical and clinical</span></p>
<p style="top:706.9pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPA183,serif;font-size:9.0pt">evidence. BMD, bone mineral density; ROS, reactive oxygen</span></p>
<p style="top:717.8pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPA183,serif;font-size:9.0pt">species.</span></p>
<p style="top:35.2pt;left:35.9pt;line-height:8.5pt"><span style="font-family:AdvPAEB9,serif;font-size:8.5pt">The Orthopaedic Journal of Sports Medicine</span></p>
<p style="top:35.2pt;left:329.8pt;line-height:8.5pt"><span style="font-family:AdvPAEB9,serif;font-size:8.5pt">Efficacy of Vitamin C After Musculoskeletal Injuries</span></p>
<p style="top:35.2pt;left:544.3pt;line-height:8.5pt"><span style="font-family:AdvPAEBA,serif;font-size:8.5pt">7</span></p>


<p style="top:71.0pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">or a placebo after either a nondisplaced or displaced distal</span></p>
<p style="top:81.9pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">radius fracture. Although other studies have suggested a</span></p>
<p style="top:92.9pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">beneficial effect of vitamin C on fracture healing in animal</span></p>
<p style="top:103.9pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">models, Ekrol and colleagues</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">6</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">found no difference in the</span></p>
<p style="top:114.9pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">Disabilities of the Arm, Shoulder and Hand (DASH) score,</span></p>
<p style="top:125.8pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">other functional outcomes, occurrence of chronic regional</span></p>
<p style="top:136.8pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">pain syndrome, or fracture healing with vitamin C treat-</span></p>
<p style="top:147.8pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">ment in patients with a distal radius fracture. It is impor-</span></p>
<p style="top:158.7pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">tant to note that functional outcomes after a distal radius</span></p>
<p style="top:169.7pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">fracture are also influenced by the condition of soft tissues</span></p>
<p style="top:180.7pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">in addition to bone healing.</span></p>
<p style="top:191.6pt;left:45.8pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">Sandukji et al</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">32</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">found that osteocalcin levels signifi-</span></p>
<p style="top:202.6pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">cantly increased in the plasma of patients treated with vita-</span></p>
<p style="top:213.5pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">min C for 2 weeks compared with those of the non&#x2013;</span></p>
<p style="top:224.5pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">antioxidant-treated group. An elevation of osteocalcin</span></p>
<p style="top:235.5pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">levels might increase BMD and consequently could acceler-</span></p>
<p style="top:246.4pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">ate healing of bone fractures because high levels of osteo-</span></p>
<p style="top:257.4pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">calcin and alkaline phosphatase have been reported to be</span></p>
<p style="top:268.4pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">positively correlated with BMD.</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">12,23,37,39</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">The authors con-</span></p>
<p style="top:279.3pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">cluded that the administration of the antioxidant vitamins</span></p>
<p style="top:290.2pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">A, E, and C, in addition to selenium, could accelerate bone</span></p>
<p style="top:301.2pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">healing after long-bone fixation surgery; therefore, antiox-</span></p>
<p style="top:312.2pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">idants could be considered in designing therapeutic proto-</span></p>
<p style="top:323.2pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">cols for postoperative bone fracture surgery.</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">32</span></sup></p>
<p style="top:334.1pt;left:45.8pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">Previous research has demonstrated that the intrave-</span></p>
<p style="top:345.1pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">nous administration of vitamin C produces a plasma con-</span></p>
<p style="top:356.1pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">centration 30- to 70-fold higher than the maximum</span></p>
<p style="top:367.0pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">tolerated oral doses.</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">27</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">This suggests that high doses given</span></p>
<p style="top:377.9pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">through intravenous administration may not be necessary,</span></p>
<p style="top:388.9pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">if not deleterious to musculoskeletal healing. However, low</span></p>
<p style="top:399.9pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">doses of vitamin C administered intravenously allows for</span></p>
<p style="top:410.8pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">optimal bioavailability of the supplement, which may pro-</span></p>
<p style="top:421.8pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">vide the means for musculoskeletal healing.</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">4,27</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">With</span></p>
<p style="top:432.8pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">regard to supplementation after musculoskeletal injuries,</span></p>
<p style="top:443.8pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">the majority of preclinical studies administering vitamin C</span></p>
<p style="top:454.7pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">parenterally observed significant benefits in the rate of</span></p>
<p style="top:465.6pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">healing and reduced oxidative stress parameters compared</span></p>
<p style="top:476.6pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">with controls.</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">5,10,19,25,33,41</span></sup></p>
<p style="top:487.6pt;left:45.8pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">Although there is a paucity of clinical studies in the liter-</span></p>
<p style="top:498.5pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">ature, 2 studies administering vitamin C orally (500 mg/d</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">2</span></sup></p>
<p style="top:509.5pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">and 1000 mg/d</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">6</span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">) did not observe significant benefits of</span></p>
<p style="top:520.5pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">vitamin C supplementation after musculoskeletal injuries</span></p>
<p style="top:531.4pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">compared with controls. However, no current studies have</span></p>
<p style="top:542.4pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">evaluated the efficacy of only vitamin C administered intra-</span></p>
<p style="top:553.3pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">venously after musculoskeletal injuries. We recognize that</span></p>
<p style="top:564.3pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">there is difficulty administering intravenous medications</span></p>
<p style="top:575.3pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">over long durations and rather suggest that intravenous</span></p>
<p style="top:586.2pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">vitamin C administration immediately postoperatively may</span></p>
<p style="top:597.2pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">have beneficial effects on musculoskeletal healing. We</span></p>
<p style="top:608.2pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">encourage future studies that attempt to delineate the</span></p>
<p style="top:619.1pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">effects of intravenous vitamin C during these recovery per-</span></p>
<p style="top:630.1pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">iods before intravenous doses can be recommended.</span></p>
<p style="top:641.1pt;left:45.8pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">A complete understanding of the mechanism of action of</span></p>
<p style="top:652.0pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">vitamin C remains unclear. Several basic science and clin-</span></p>
<p style="top:663.0pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">ical studies investigating tumor development have reported</span></p>
<p style="top:673.9pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">that the overexpression of antioxidant enzymes and high</span></p>
<p style="top:684.9pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">doses of vitamin C (ie,</span><span style="font-family:AdvP4C4E74,serif;font-size:9.0pt"> &#xfffd;</span><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">1000 mg/d) may impair wound</span></p>
<p style="top:695.9pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">healing and angiogenesis.</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">29,30,36,40</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">Although high concen-</span></p>
<p style="top:706.8pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">trations of ROS can be deleterious to tissue healing, low</span></p>
<p style="top:717.8pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">concentrations of ROS have been demonstrated to promote</span></p>
<p style="top:71.0pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">angiogenesis and mesenchymal stem cell proliferation.</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">3</span></sup></p>
<p style="top:82.1pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">Therefore, it has been hypothesized that overscavenging</span></p>
<p style="top:93.1pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">of ROS by vitamin C may impair healing in musculoskeletal</span></p>
<p style="top:104.2pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">injury settings.</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">19</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">Sandukji et al</span><sup><span style="font-family:AdvPAEB8,serif;font-size:6.3pt">32</span></sup><sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt"> </span></sup><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">reported increased bio-</span></p>
<p style="top:115.3pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">markers of bone with 60 mg/d of vitamin C, which provides</span></p>
<p style="top:126.3pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">clinical evidence for the use of low doses of vitamin C as a</span></p>
<p style="top:137.4pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">postinjury supplement. Therefore, we recommend that the</span></p>
<p style="top:148.5pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">low-dose oral administration (ie, 60 mg/d) of vitamin C may</span></p>
<p style="top:159.6pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">be an effective form of treatment after musculoskeletal</span></p>
<p style="top:170.6pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">injuries. However, there are currently no definitive treat-</span></p>
<p style="top:181.7pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">ment protocols for the administration of vitamin C. Further</span></p>
<p style="top:192.7pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">clinical studies analyzing a broader range of oral doses, the</span></p>
<p style="top:203.8pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">efficacy of vitamin C administration via parental routes,</span></p>
<p style="top:214.8pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">and the synergistic actions of combined antioxidant admin-</span></p>
<p style="top:226.0pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">istration are encouraged.</span></p>
<p style="top:255.0pt;left:306.4pt;line-height:10.0pt"><span style="font-family:AdvPA183,serif;font-size:10.0pt">Limitations</span></p>
<p style="top:275.7pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">We acknowledge some limitations to this systematic</span></p>
<p style="top:286.8pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">review. Although vitamin C is a well-known supplement</span></p>
<p style="top:297.9pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">that is used frequently, only 10 studies were included after</span></p>
<p style="top:308.9pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">the specific inclusion criteria were applied, which reflects</span></p>
<p style="top:320.0pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">the overall lack of evidence-based literature regarding vita-</span></p>
<p style="top:331.1pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">min C supplementation after musculoskeletal injuries. The</span></p>
<p style="top:342.1pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">heterogeneity in vitamin C supplementation protocols,</span></p>
<p style="top:353.2pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">including the route of administration, dosage, frequency,</span></p>
<p style="top:364.3pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">and duration, limits direct comparisons when evaluating</span></p>
<p style="top:375.3pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">combined results. Furthermore, variations in the type of</span></p>
<p style="top:386.4pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">collagen (bone, tendon, ligament) studied and the treat-</span></p>
<p style="top:397.4pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">ment methods (conservative vs surgical) used limit the</span></p>
<p style="top:408.5pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">global interpretation of results on vitamin C supplementa-</span></p>
<p style="top:419.6pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">tion. One clinical study evaluated the effects of only vita-</span></p>
<p style="top:430.7pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">min C supplementation, and 2 studies evaluated the effects</span></p>
<p style="top:441.7pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">of the combined supplementation of vitamin C and other</span></p>
<p style="top:452.8pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">antioxidants; this may affect the clinical findings and direct</span></p>
<p style="top:463.8pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">interpretation of vitamin C. In addition, no clinical studies</span></p>
<p style="top:474.9pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">evaluated the evidence for tendon healing after vitamin C</span></p>
<p style="top:486.0pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">supplementation. Also, there were differences in the injury</span></p>
<p style="top:497.1pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">location (ie, hand, wrist, knee), so the results may not be</span></p>
<p style="top:508.1pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">generalizable to other injury locations in the body (ie,</span></p>
<p style="top:519.2pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">shoulder, hip, ankle). In addition, because rats are capable</span></p>
<p style="top:530.2pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">of synthesizing vitamin C through a normal diet, a function</span></p>
<p style="top:541.3pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">that humans do not exhibit, this is a direct limitation of the</span></p>
<p style="top:552.4pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">preclinical studies. It is suggested that further preclinical</span></p>
<p style="top:563.4pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">studies be performed on animals that also do not contain</span></p>
<p style="top:574.5pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">this trait, including chickens, guinea pigs, and primates,</span></p>
<p style="top:585.6pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">which can isolate the effects of exogenous vitamin C.</span></p>
<p style="top:619.6pt;left:306.4pt;line-height:10.0pt"><span style="font-family:AdvPA183,serif;font-size:10.0pt">CONCLUSION</span></p>
<p style="top:640.4pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">Preclinical studies demonstrated that vitamin C has the</span></p>
<p style="top:651.4pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">potential to accelerate bone healing after fractures,</span></p>
<p style="top:662.5pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">increase type I collagen synthesis, and reduce oxidative</span></p>
<p style="top:673.5pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">stress parameters. No adverse effects were reported with</span></p>
<p style="top:684.6pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">vitamin C supplementation in either animal models or</span></p>
<p style="top:695.7pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">human participants; thus, oral vitamin C appears to be a</span></p>
<p style="top:706.8pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">safe supplement but lacks clinical evidence compared with</span></p>
<p style="top:717.8pt;left:306.4pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">controls. Because of the limited number of human studies,</span></p>
<p style="top:35.2pt;left:35.9pt;line-height:8.5pt"><span style="font-family:AdvPAEBA,serif;font-size:8.5pt">8</span></p>
<p style="top:35.2pt;left:50.7pt;line-height:8.5pt"><span style="font-family:AdvPAEB9,serif;font-size:8.5pt">DePhillipo et al</span></p>
<p style="top:35.2pt;left:374.3pt;line-height:8.5pt"><span style="font-family:AdvPAEB9,serif;font-size:8.5pt">The Orthopaedic Journal of Sports Medicine</span></p>


<p style="top:71.0pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">further clinical investigations are needed before the imple-</span></p>
<p style="top:81.9pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPAEB8,serif;font-size:9.0pt">mentation of vitamin C as a postinjury supplement.</span></p>
<p style="top:108.9pt;left:35.9pt;line-height:9.0pt"><span style="font-family:AdvPA189,serif;font-size:9.0pt">REFERENCES</span></p>
<p style="top:128.0pt;left:39.6pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">1. Badr G, Hozzein WN, Badr BM, Al Ghamdi A, Saad Eldien HM, Gar-</span></p>
<p style="top:137.5pt;left:49.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">raud O. Bee venom accelerates wound healing in diabetic mice by</span></p>
<p style="top:146.9pt;left:49.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">suppressing activating transcription factor-3 (ATF-3) and inducible</span></p>
<p style="top:156.4pt;left:49.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">nitric oxide synthase (iNOS)-mediated oxidative stress and recruiting</span></p>
<p style="top:165.9pt;left:49.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">bone marrow-derived endothelial progenitor cells.</span><span style="font-family:AdvPA186,serif;font-size:7.5pt"> J Cell Physiol</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">.</span></p>
<p style="top:175.3pt;left:49.6pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">2016;231(10):2159-2171.</span></p>
<p style="top:184.8pt;left:39.6pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">2. Barker T, Leonard SW, Hansen J, et al. Vitamin E and C supplemen-</span></p>
<p style="top:194.3pt;left:49.6pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">tation does not ameliorate muscle dysfunction after anterior cruciate</span></p>
<p style="top:203.7pt;left:49.6pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">ligament surgery.</span><span style="font-family:AdvPA186,serif;font-size:7.5pt"> Free Radic Biol Med</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">. 2009;47(11):1611-1618.</span></p>
<p style="top:213.2pt;left:39.6pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">3. Chan EC, Jiang F, Peshavariya HM, Dusting GJ. Regulation of cell</span></p>
<p style="top:222.7pt;left:49.6pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">proliferation by NADPH oxidase-mediated signaling: potential roles in</span></p>
<p style="top:232.1pt;left:49.6pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">tissue repair, regenerative medicine and tissue engineering.</span><span style="font-family:AdvPA186,serif;font-size:7.5pt"> Pharma-</span></p>
<p style="top:241.6pt;left:49.6pt;line-height:7.5pt"><span style="font-family:AdvPA186,serif;font-size:7.5pt">col Ther</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">. 2009;122(2):97-108.</span></p>
<p style="top:251.1pt;left:39.6pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">4. Duconge J, Miranda-Massari JR, Gonzalez MJ, Jackson JA, Warnock</span></p>
<p style="top:260.5pt;left:49.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">W, Riordan NH. Pharmacokinetics of vitamin C: insights into the oral</span></p>
<p style="top:269.9pt;left:49.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">and intravenous administration of ascorbate.</span><span style="font-family:AdvPA186,serif;font-size:7.5pt"> P R Health Sci J</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">. 2008;</span></p>
<p style="top:279.4pt;left:49.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">27(1):7-19.</span></p>
<p style="top:288.9pt;left:39.6pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">5. Duygulu F, Yakan B, Karaoglu S, Kutlubay R, Karahan OI, Ozturk A.</span></p>
<p style="top:298.3pt;left:49.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">The effect of zymosan and the protective effect of various antioxi-</span></p>
<p style="top:307.8pt;left:49.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">dants on fracture healing in rats.</span><span style="font-family:AdvPA186,serif;font-size:7.5pt"> Arch Orthop Trauma Surg</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">. 2007;</span></p>
<p style="top:317.3pt;left:49.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">127(7):493-501.</span></p>
<p style="top:326.7pt;left:39.6pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">6. Ekrol I, Duckworth AD, Ralston SH, Court-Brown CM, McQueen MM.</span></p>
<p style="top:336.2pt;left:49.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">The influence of vitamin C on the outcome of distal radial fractures: a</span></p>
<p style="top:345.7pt;left:49.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">double-blind, randomized controlled trial.</span><span style="font-family:AdvPA186,serif;font-size:7.5pt"> J Bone Joint Surg Am</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">.</span></p>
<p style="top:355.2pt;left:49.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">2014;96(17):1451-1459.</span></p>
<p style="top:364.6pt;left:39.6pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">7. Fazzalari NL, Forwood MR, Smith K, Manthey BA, Herreen P. Assess-</span></p>
<p style="top:374.1pt;left:49.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">ment of cancellous bone quality in severe osteoarthrosis: bone min-</span></p>
<p style="top:383.6pt;left:49.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">eral density, mechanics, and microdamage.</span><span style="font-family:AdvPA186,serif;font-size:7.5pt"> Bone</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">. 1998;22(4):</span></p>
<p style="top:393.0pt;left:49.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">381-388.</span></p>
<p style="top:402.5pt;left:39.6pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">8. Franceschi RT, Iyer BS, Cui Y. Effects of ascorbic acid on collagen</span></p>
<p style="top:412.0pt;left:49.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">matrix formation and osteoblast differentiation in murine MC3T3-E1</span></p>
<p style="top:421.4pt;left:49.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">cells.</span><span style="font-family:AdvPA186,serif;font-size:7.5pt"> J Bone Miner Res</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">. 1994;9(6):843-854.</span></p>
<p style="top:430.8pt;left:39.6pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">9. Franceschi RT, Wilson JX, Dixon SJ. Requirement for Na(</span><span style="font-family:AdvP4C4E74,serif;font-size:7.5pt">&#xfe;</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">)-dependent</span></p>
<p style="top:440.3pt;left:49.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">ascorbic acid transport in osteoblast function.</span><span style="font-family:AdvPA186,serif;font-size:7.5pt"> Am J Physiol</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">. 1995;</span></p>
<p style="top:449.8pt;left:49.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">268(6 pt 1):C1430-C1439.</span></p>
<p style="top:459.2pt;left:35.9pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">10. Fu SC, Cheng WH, Cheuk YC, et al. Development of vitamin C irriga-</span></p>
<p style="top:468.7pt;left:49.9pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">tion saline to promote graft healing in anterior cruciate ligament</span></p>
<p style="top:478.2pt;left:49.9pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">reconstruction.</span><span style="font-family:AdvPA186,serif;font-size:7.5pt"> J Orthop Trans</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">. 2013;1:67-77.</span></p>
<p style="top:487.6pt;left:35.9pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">11. Ganta DR, McCarthy MB, Gronowicz GA. Ascorbic acid alters colla-</span></p>
<p style="top:497.1pt;left:49.9pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">gen integrins in bone culture.</span><span style="font-family:AdvPA186,serif;font-size:7.5pt"> Endocrinology</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">. 1997;138(9):3606-3612.</span></p>
<p style="top:506.6pt;left:35.9pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">12. Garnero P, Delmas PD. Contribution of bone mineral density and</span></p>
<p style="top:516.0pt;left:50.2pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">bone turnover markers to the estimation of risk of osteoporotic frac-</span></p>
<p style="top:525.5pt;left:50.2pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">ture in postmenopausal women.</span><span style="font-family:AdvPA186,serif;font-size:7.5pt"> J Musculoskelet Neuronal Interact</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">.</span></p>
<p style="top:535.0pt;left:50.2pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">2004;4(1):50-63.</span></p>
<p style="top:544.4pt;left:35.9pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">13. Garnero P, Delmas PD. Noninvasive techniques for assessing skeletal</span></p>
<p style="top:553.9pt;left:49.9pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">changes in inflammatory arthritis: bone biomarkers.</span><span style="font-family:AdvPA186,serif;font-size:7.5pt"> Curr Opin Rheu-</span></p>
<p style="top:563.4pt;left:49.9pt;line-height:7.5pt"><span style="font-family:AdvPA186,serif;font-size:7.5pt">matol</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">. 2004;16(4):428-434.</span></p>
<p style="top:572.8pt;left:35.9pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">14. Garrett IR, Boyce BF, Oreffo RO, Bonewald L, Poser J, Mundy GR.</span></p>
<p style="top:582.3pt;left:49.9pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">Oxygen-derived free radicals stimulate osteoclastic bone resorp-</span></p>
<p style="top:591.8pt;left:49.9pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">tion in rodent bone in vitro and in vivo.</span><span style="font-family:AdvPA186,serif;font-size:7.5pt"> J Clin Invest</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">. 1990;85(3):</span></p>
<p style="top:601.2pt;left:49.9pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">632-639.</span></p>
<p style="top:610.7pt;left:35.9pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">15. Giordano V, Albuquerque RP, do Amaral NP, Chame CC, de Souza F,</span></p>
<p style="top:620.1pt;left:49.9pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">Apfel MI. Supplementary vitamin C does not accelerate bone healing</span></p>
<p style="top:629.6pt;left:49.9pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">in a rat tibia fracture model.</span><span style="font-family:AdvPA186,serif;font-size:7.5pt"> Acta Ortop Bras</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">. 2012;20(1):10-12.</span></p>
<p style="top:639.1pt;left:35.9pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">16. Gokturk E, Turgut A, Baycu C, Gunal I, Seber S, Gulbas Z. Oxygen-</span></p>
<p style="top:648.5pt;left:49.9pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">free radicals impair fracture healing in rats.</span><span style="font-family:AdvPA186,serif;font-size:7.5pt"> Acta Orthop Scand</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">. 1995;</span></p>
<p style="top:658.0pt;left:49.9pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">66(5):473-475.</span></p>
<p style="top:667.5pt;left:35.9pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">17. Haigler HJ, Spring DD. Comparison of the analgesic effects of</span></p>
<p style="top:676.9pt;left:50.6pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">dimethyl sulfoxide and morphine.</span><span style="font-family:AdvPA186,serif;font-size:7.5pt"> Ann N Y Acad Sci</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">. 1983;411:19-27.</span></p>
<p style="top:686.4pt;left:35.9pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">18. Harada S, Matsumoto T, Ogata E. Role of ascorbic acid in the regu-</span></p>
<p style="top:695.9pt;left:49.9pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">lation of proliferation in osteoblast-like MC3T3-E1 cells.</span><span style="font-family:AdvPA186,serif;font-size:7.5pt"> J Bone Miner</span></p>
<p style="top:705.3pt;left:49.9pt;line-height:7.5pt"><span style="font-family:AdvPA186,serif;font-size:7.5pt">Res</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">. 1991;6(9):903-908.</span></p>
<p style="top:71.1pt;left:306.4pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">19. Hung LK, Fu SC, Lee YW, Mok TY, Chan KM. Local vitamin-C injec-</span></p>
<p style="top:80.8pt;left:320.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">tion reduced tendon adhesion in a chicken model of flexor digitorum</span></p>
<p style="top:90.5pt;left:320.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">profundus tendon injury.</span><span style="font-family:AdvPA186,serif;font-size:7.5pt"> J Bone Joint Surg Am</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">. 2013;95(7):e41.</span></p>
<p style="top:100.0pt;left:306.4pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">20. Kjaer M, Langberg H, Heinemeier K, et al. From mechanical loading to</span></p>
<p style="top:109.6pt;left:320.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">collagen synthesis, structural changes and function in human tendon.</span></p>
<p style="top:119.3pt;left:320.5pt;line-height:7.5pt"><span style="font-family:AdvPA186,serif;font-size:7.5pt">Scand J Med Sci Sports</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">. 2009;19(4):500-510.</span></p>
<p style="top:128.8pt;left:306.4pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">21. Lee YW, Fu SC, Yeung MY, Lau CML, Chan KM, Hung LK. Effects of</span></p>
<p style="top:138.5pt;left:320.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">redox modulation on cell proliferation, viability, and migration in cul-</span></p>
<p style="top:148.2pt;left:320.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">tured rat and human tendon progenitor cells.</span><span style="font-family:AdvPA186,serif;font-size:7.5pt"> Oxid Med Cell Longev</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">.</span></p>
<p style="top:157.8pt;left:320.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">2017;2017:8785042.</span></p>
<p style="top:167.3pt;left:306.4pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">22. Manela-Azulay M, Bagatin E. Cosmeceuticals vitamins.</span><span style="font-family:AdvPA186,serif;font-size:7.5pt"> Clin Derma-</span></p>
<p style="top:177.0pt;left:320.5pt;line-height:7.5pt"><span style="font-family:AdvPA186,serif;font-size:7.5pt">tol</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">. 2009;27(5):469-474.</span></p>
<p style="top:186.4pt;left:306.4pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">23. Mimori K, Komaki M, Iwasaki K, Ishikawa I. Extracellular signal-</span></p>
<p style="top:196.1pt;left:320.9pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">regulated kinase 1/2 is involved in ascorbic acid-induced osteoblastic</span></p>
<p style="top:205.8pt;left:320.9pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">differentiation in periodontal ligament cells.</span><span style="font-family:AdvPA186,serif;font-size:7.5pt"> J Periodontol</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">. 2007;78(2):</span></p>
<p style="top:215.5pt;left:320.9pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">328-334.</span></p>
<p style="top:224.9pt;left:306.4pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">24. Murad S, Grove D, Lindberg KA, Reynolds G, Sivarajah A, Pinnell SR.</span></p>
<p style="top:234.6pt;left:320.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">Regulation of collagen synthesis by ascorbic acid.</span><span style="font-family:AdvPA186,serif;font-size:7.5pt"> Proc Natl Acad Sci</span></p>
<p style="top:244.3pt;left:320.5pt;line-height:7.5pt"><span style="font-family:AdvPA186,serif;font-size:7.5pt">U S A</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">. 1981;78(5):2879-2882.</span></p>
<p style="top:253.8pt;left:306.4pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">25. Omeroglu S, Peker T, Turkozkan N, Omeroglu H. High-dose vitamin C</span></p>
<p style="top:263.5pt;left:320.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">supplementation accelerates the Achilles tendon healing in healthy</span></p>
<p style="top:273.1pt;left:320.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">rats.</span><span style="font-family:AdvPA186,serif;font-size:7.5pt"> Arch Orthop Trauma Surg</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">. 2009;129(2):281-286.</span></p>
<p style="top:282.6pt;left:306.4pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">26. Otsuka E, Yamaguchi A, Hirose S, Hagiwara H. Characterization of</span></p>
<p style="top:292.3pt;left:320.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">osteoblastic differentiation of stromal cell line ST2 that is induced by</span></p>
<p style="top:302.0pt;left:320.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">ascorbic acid.</span><span style="font-family:AdvPA186,serif;font-size:7.5pt"> Am J Physiol</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">. 1999;277(1 pt 1):C132-C138.</span></p>
<p style="top:311.4pt;left:306.4pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">27. Padayatty SJ, Sun H, Wang Y, et al. Vitamin C pharmacokinetics:</span></p>
<p style="top:321.1pt;left:320.6pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">implications for oral and intravenous use.</span><span style="font-family:AdvPA186,serif;font-size:7.5pt"> Ann Intern Med</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">. 2004;</span></p>
<p style="top:330.8pt;left:320.6pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">140(7):533-537.</span></p>
<p style="top:340.2pt;left:306.4pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">28. Phillips CL, Combs SB, Pinnell SR. Effects of ascorbic acid on prolif-</span></p>
<p style="top:349.9pt;left:320.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">eration and collagen synthesis in relation to the donor age of human</span></p>
<p style="top:359.6pt;left:320.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">dermal fibroblasts.</span><span style="font-family:AdvPA186,serif;font-size:7.5pt"> J Invest Dermatol</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">. 1994;103(2):228-232.</span></p>
<p style="top:369.1pt;left:306.4pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">29. Redondo P, Jimenez E, Perez A, Garcia-Foncillas J. N-acetylcysteine</span></p>
<p style="top:378.8pt;left:320.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">downregulates vascular endothelial growth factor production by</span></p>
<p style="top:388.4pt;left:320.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">human keratinocytes in vitro.</span><span style="font-family:AdvPA186,serif;font-size:7.5pt"> Arch Dermatol Res</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">. 2000;292(12):</span></p>
<p style="top:398.1pt;left:320.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">621-628.</span></p>
<p style="top:407.6pt;left:306.4pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">30. Roy S, Khanna S, Nallu K, Hunt TK, Sen CK. Dermal wound healing is</span></p>
<p style="top:417.3pt;left:320.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">subject to redox control.</span><span style="font-family:AdvPA186,serif;font-size:7.5pt"> Mol Ther</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">. 2006;13(1):211-220.</span></p>
<p style="top:426.8pt;left:306.4pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">31. Russell JE, Manske PR. Ascorbic acid requirement for optimal flexor</span></p>
<p style="top:436.5pt;left:320.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">tendon repair in vitro.</span><span style="font-family:AdvPA186,serif;font-size:7.5pt"> J Orthop Res</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">. 1991;9(5):714-719.</span></p>
<p style="top:445.9pt;left:306.4pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">32. Sandukji A, Al-Sawaf H, Mohamadin A, Alrashidi Y, Sheweita SA.</span></p>
<p style="top:455.6pt;left:320.7pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">Oxidative stress and bone markers in plasma of patients with long-</span></p>
<p style="top:465.3pt;left:320.7pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">bone fixative surgery: role of antioxidants.</span><span style="font-family:AdvPA186,serif;font-size:7.5pt"> Hum Exp Toxicol</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">. 2011;</span></p>
<p style="top:475.0pt;left:320.7pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">30(6):435-442.</span></p>
<p style="top:484.4pt;left:306.4pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">33. Sarisozen B, Durak K, Dincer G, Bilgen OF. The effects of vitamins E</span></p>
<p style="top:494.1pt;left:320.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">and C on fracture healing in rats.</span><span style="font-family:AdvPA186,serif;font-size:7.5pt"> J Int Med Res</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">. 2002;30(3):309-313.</span></p>
<p style="top:503.5pt;left:306.4pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">34. Shaw G, Lee-Barthel A, Ross ML, Wang B, Baar K. Vitamin</span></p>
<p style="top:513.2pt;left:321.7pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">C-enriched gelatin supplementation before intermittent activity aug-</span></p>
<p style="top:522.9pt;left:321.7pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">ments collagen synthesis.</span><span style="font-family:AdvPA186,serif;font-size:7.5pt"> Am J Clin Nutr</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">. 2017;105(1):136-143.</span></p>
<p style="top:532.4pt;left:306.4pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">35. Taylor AK, Lueken SA, Libanati C, Baylink DJ. Biochemical markers of</span></p>
<p style="top:542.1pt;left:320.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">bone turnover for the clinical assessment of bone metabolism.</span><span style="font-family:AdvPA186,serif;font-size:7.5pt"> Rheum</span></p>
<p style="top:551.7pt;left:320.5pt;line-height:7.5pt"><span style="font-family:AdvPA186,serif;font-size:7.5pt">Dis Clin North Am</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">. 1994;20(3):589-607.</span></p>
<p style="top:561.2pt;left:306.4pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">36. Verrax J, Calderon PB. Pharmacologic concentrations of ascorbate</span></p>
<p style="top:570.9pt;left:320.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">are achieved by parenteral administration and exhibit antitumoral</span></p>
<p style="top:580.6pt;left:320.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">effects.</span><span style="font-family:AdvPA186,serif;font-size:7.5pt"> Free Radic Biol Med</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">. 2009;47(1):32-40.</span></p>
<p style="top:590.0pt;left:306.4pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">37. Weber P. The role of vitamins in the prevention of osteoporosis: a brief</span></p>
<p style="top:599.7pt;left:320.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">status report.</span><span style="font-family:AdvPA186,serif;font-size:7.5pt"> Int J Vitam Nutr Res</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">. 1999;69(3):194-197.</span></p>
<p style="top:609.2pt;left:306.4pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">38. Wright JG, Swiontkowski MF, Heckman JD. Introducing levels of evi-</span></p>
<p style="top:618.8pt;left:320.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">dence to the journal.</span><span style="font-family:AdvPA186,serif;font-size:7.5pt"> J Bone Joint Surg Am</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">. 2003;85(1):1-3.</span></p>
<p style="top:628.3pt;left:306.4pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">39. Wu X, Itoh N, Taniguchi T, et al. Zinc-induced sodium-dependent</span></p>
<p style="top:638.0pt;left:320.7pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">vitamin C transporter 2 expression: potent roles in osteoblast differ-</span></p>
<p style="top:647.7pt;left:320.7pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">entiation.</span><span style="font-family:AdvPA186,serif;font-size:7.5pt"> Arch Biochem Biophys</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">. 2003;420(1):114-120.</span></p>
<p style="top:657.2pt;left:306.4pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">40. Yasuda M, Ohzeki Y, Shimizu S, et al. Stimulation of in vitro angio-</span></p>
<p style="top:666.9pt;left:320.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">genesis by hydrogen peroxide and the relation with ETS-1 in endo-</span></p>
<p style="top:676.5pt;left:320.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">thelial cells.</span><span style="font-family:AdvPA186,serif;font-size:7.5pt"> Life Sci</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">. 1999;64(4):249-258.</span></p>
<p style="top:686.0pt;left:306.4pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">41. Yilmaz C, Erdemli E, Selek H, Kinik H, Arikan M, Erdemli B. The con-</span></p>
<p style="top:695.7pt;left:320.5pt;line-height:7.5pt"><span style="font-family:AdvPA183,serif;font-size:7.5pt">tribution of vitamin C to healing of experimental fractures.</span><span style="font-family:AdvPA186,serif;font-size:7.5pt"> Arch</span></p>
<p style="top:705.4pt;left:320.5pt;line-height:7.5pt"><span style="font-family:AdvPA186,serif;font-size:7.5pt">Orthop Trauma Surg</span><span style="font-family:AdvPA183,serif;font-size:7.5pt">. 2001;121(7):426-428.</span></p>
<p style="top:35.2pt;left:35.9pt;line-height:8.5pt"><span style="font-family:AdvPAEB9,serif;font-size:8.5pt">The Orthopaedic Journal of Sports Medicine</span></p>
<p style="top:35.2pt;left:329.8pt;line-height:8.5pt"><span style="font-family:AdvPAEB9,serif;font-size:8.5pt">Efficacy of Vitamin C After Musculoskeletal Injuries</span></p>
<p style="top:35.2pt;left:544.3pt;line-height:8.5pt"><span style="font-family:AdvPAEBA,serif;font-size:8.5pt">9</span></p>

</div>
